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Abstract
Major depressive disorder (MDD) is characterized by emotional distress and cognitive
dysfunction that lasts for at least two weeks and significantly impairs one’s ability to function at
home and at work. Cognitive deficits in domains such as processing speed, memory retention, and
executive function can persist beyond the remission of emotional symptoms, which is why it is
imperative to develop antidepressants that address cognitive dysfunction. Healthy cognitive
function relies on synaptic plasticity, which strengthens communication between cells and is
measured in terms of long-term potentiation (LTP). LTP is triggered when activation of AMPA
and NMDA receptors leads to an influx of Ca2+ ions into the cell, and appears to be related to
increased AMPA receptor expression. Ketamine, an NMDA receptor antagonist and putative fastacting antidepressant, results in acute psychotomimetic side effects due to its obstruction of
glutamatergic activity at NMDARs. However, 24 hours post-administration, ketamine enhances
LTP in the Cornu Ammonis 1 (CA1) region of the hippocampus in rats and enhances AMPA
receptor expression. One of ketamine’s metabolites, (2R,6R)-hydroxynorketamine (HNK),
manages to enhance AMPA receptor activity in the CA1 of the hippocampus 24 hours postadministration with negligible affinity for the noncompetitive NMDA receptor site, hence avoiding
undesirable acute side effects. In rodents, the Novel Object Placement (OP) task is used to assess
spatial memory and is dependent on hippocampal function. Therefore, we hypothesized an
increase in hippocampal AMPA expression 24 hours post-administration of (2R,6R)-HNK
compared to vehicle, which should then result in improved performance in the OP task due to
enhanced hippocampal AMPA activity. Our data confirms the increase in hippocampal AMPA
expression, but does not reflect this increase in enhanced spatial memory performance in the OP
task. Further research is needed on the use of the OP task in conjunction with (2R,6R)-HNK to
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investigate spatial memory performance, as this may be the first study to do so and thus requires
replication. The effects of (2R,6R)-HNK on AMPA expression must also be studied using a
chronic stress model with both male and female rats. Differences in glutamatergic
neurotransmission that result from chronic stress may help elucidate the mechanisms by which
(2R,6R)-HNK exerts its effects.
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The Effects of (2R,6R)-hydroxynorketamine (HNK) on Hippocampal -amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA) Expression and Novel Object Placement
Performance in Long Evans Rats
Major depressive disorder (MDD) is a mood disorder characterized by the principle
symptoms of depressed, low mood, agitation, or loss of pleasure in previously enjoyable activities,
along with symptoms of fatigue, worthlessness, sleep abnormalities, or significant changes in diet
that persist for at least 2 weeks (American Psychiatric Association, 2013). MDD is a major global
health concern because of its risk of onset at an early age, high rates of lifetime prevalence, and
risk of relapse after cessation of treatment. Depressive disorders span across cultures and ages, and
currently affect 322 million people worldwide (World Health Organization, 2017).
Sixty-four percent of adults and 71% of adolescents in the United States experience “severe
impairment” during a depressive episode (National Institute of Mental Health, 2019). These
impairments noticeably weaken an individual’s ability to function in their roles at home and at
work. Such impairments include reduced psychomotor speed, slow response times, poor memory
retention, trouble concentrating, and poor self-perceived workplace performance and productivity
that all worsen as severity of depression increases (Naismith et al, 2007; McIntyre et al, 2015).
These cognitive dysfunctions are a growing concern for individuals with MDD because they can
be independent of the emotional symptoms of depression. Roiser and Sahakian (2013) draw a
distinction between cognition that is “hot”, which is tied to emotional input, and cognition that is
“cold”, which is independent of emotional input. MDD-associated impairments in hot cognition
include biases in attention and memory toward negatively valanced stimuli, anhedonia, and
catastrophic thinking. Impairments in cold cognition include reduced processing speed, and
attention deficits. Though cognitive impairments occur in both these domains, those that occur in
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cold cognition are widely undertreated and more likely to persist after remission of depression
(Roiser & Sahakian, 2013). Compared to healthy individuals, those who have remitted from
depression still display poor neurocognitive ability in domains related to memory and attention,
and many experience a diminished quality of life as a direct result (Baune et al, 2010; Shimizu et
al, 2013). Further evidence of this idea comes from Jaeger and colleagues (2005), who found that
neurocognitive deficits and their severity are strongly predictive of daily-life function 6 months
after being hospitalized for depression. These data suggest that despite emotionally recovering
from depression, an individual can still suffer from residual cognitive difficulties.

MDD, Cognitive Dysfunction, and Current Treatment Options
Cognitive dysfunction is not unique to depression. Many anxiety and stress disorders
persist because of cognitive distortions such as rumination and catastrophizing. Schizophrenia is
known for its impairments in executive function, with working memory deficits being a core
neurocognitive dysfunction (Silver et al, 2003; Barch et al, 2003). Working memory deficits then
limit the ability to perform more complex tasks that require executive function such as decisionmaking and evaluations of risk. Individuals with schizophrenia also perform poorer and show
greater neural abnormalities than individuals with MDD in working memory tasks (Barch et al,
2003). Further, anxiety and stress disorders are characteristically defined by deficits in cognitive
flexibility, which is the ability to change one’s ingrained thought patterns after input from one’s
experiences (Park & Moghaddam, 2017). Cognitive inflexibility is a combination of negative
attentional biases and impaired decision-making, and it is established through the formation of
negative self-referential schemas (Disner, 2011). These schemas are formed through the
experience of recurrent adverse events, which then behave as a feedback loop of rumination and
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negative response styles. The continued experience of anxiety and stress solidifies cognitive
inflexibility. Cognitive flexibility also includes the ability to adjust one’s mental representation of
spatial awareness (i.e. imagining your bedroom with a different layout), which requires control
over one’s executive functioning and working memory (Diamond, 2013). Unfortunately, over 50%
of individuals with depression experience comorbidities with some form of anxiety, stress, or panic
disorder, which worsens emotional and cognitive dysfunctions in depression and reduces
responsiveness to treatment (Richards, 2011; Jones, Chase, & Fournier, 2016). Therefore,
cognitive deficits play a major role in maintaining depression. It is therefore crucial to give greater
urgency to the treatment of cognitive symptoms and to the development of therapies that reduce
the time of relief onset and that are not limited in terms of population efficacy.
Currently, one of the main courses of treatment for depression is cognitive behavioral
therapy, or CBT (Beck, 1997; Salkovskis, 1996). CBT focuses on training an individual to replace
maladaptive streams of thought with goal-oriented thoughts and behaviors and to apply those skills
in their everyday life. A meta-analysis conducted by Butler et al. (2005) reviewed the effectiveness
of CBT in improving psychiatric symptoms against other stress management therapies and
behavioral therapies. CBT was the superior method of treatment for lowering symptoms in
obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, anger management,
generalized anxiety, and unipolar depression. However, CBT is primarily useful in lowering
maladaptive emotion-related symptoms, and has yet to be shown to directly lower cognitive
impairment (Butler et al, 2005). It is also unclear as to how the beneficial effects of CBT can be
prolonged indefinitely beyond cessation of treatment.
Aside from psychotherapy, the most common course of action against MDD is
pharmacological treatment with selective serotonin reuptake inhibitors, or SSRIs (Kurian, Greer,
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& Trivedi, 2009; Clevenger et al, 2018). At least 65% of adults and 20% of adolescents diagnosed
with depression and currently in treatment receive some form of pharmacological treatment
(National Institute of Mental Health, 2019). Despite this, only 1/3 of these individuals experience
remission over the course of their treatment (Kurian, Greer, & Trivedi, 2009). Even more
frustrating is that, despite the popularity of these drugs, antidepressants currently on the market
are slow-acting and work for limited populations, with many individuals searching for the “right”
antidepressant through years of trial and error (Machado-Vieira et al, 2009; Kurian, Greer, &
Trivedi, 2009).
SSRIs function by inhibiting the reuptake of serotonin by presynaptic neurons in order to
allow more serotonin to remain in the synaptic cleft (Sangkuhl, Klein, & Altman, 2009). Serotonin
(5-hydroxytryptamine; 5-HT) is a neurotransmitter involved in various neural processes including
cognitive function, emotion regulation, and reward processing. Normal functioning of the
serotonergic system ensures proper neuromodulation of behaviors in response to stress, and low
levels of serotonin may be associated with a number of affective and behavioral disorders,
including depression (Strüder & Weicker, 2001; Gellynck et al, 2013). However, it is important to
note that investigations of serotonin transmission in depression mainly focus on the effects of
SSRIs instead of on baseline transmission in drug-free depressed patients. Therefore, it is difficult
to properly assess the role of serotonin in the development and maintenance of depression. Another
drawback of SSRIs is that they do not adequately target cognitive deficits, a sorely unmet need in
this population (Kurian, Greer, & Trivedi, 2009).
Preliminary work with the antidepressant vortioxetine shows a reversal of spatial memory
and recognition memory impairments in that is not seen by escitalopram, an SSRI, or duloxetine,
which is a serotonin-norepinephrine reuptake inhibitor or SNRI (du Jardin et al, 2014; Jensen et
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al, 2014). In humans, vortioxetine was associated with improvements in verbal learning and
processing speed that were dissociated from response to mood symptoms in a group of elderly
depressed patients (Katona, Hansen, & Olsen, 2012). Vortioxetine has also been compared to
placebo in its effects on cognitive function in adults with recurrent moderate to severe depression.
Over the course of this 8-week placebo-controlled study, participants were assessed on cognitive
function via tasks such as the Digit Symbol Substitution Test (DSST) and self-report
questionnaires, and were assessed on overall depressive symptoms via the Montgomery-Åsberg
Depression Rating Scale, or MADRS (McIntyre, Lophaven, & Olsen, 2014). The DSST primarily
assesses processing speed and executive function, both of which are cognitive abilities heavily
impacted by depression. After 8 weeks of treatment, vortioxetine significantly improved cognitive
performance compared to placebo in the DSST (with effect sizes of 0.51 for 10 mg of vortioxetine
and 0.52 for 20 mg of vortioxetine), auditory verbal learning tests, and simple reaction time tasks
(McIntyre, Lophaven, & Olsen, 2014). As for the response in depressive symptoms, improvements
compared to placebo were seen after 1 week of 20 mg of vortioxetine and after 4 weeks of 10 mg
of vortioxetine.
Thus, it appears that vortioxetine has unique effects on cognitive function in depressed
patients. Current theory on vortioxetine’s mechanism of action suggest that these effects may be
caused by indirect increases in glutamate neurotransmission. Vortioxetine acts as an agonist at the
5-HT1A receptor, a partial agonist at 5-HT1B receptors, an antagonist at the 5-HT3, 5-HT7, and 5HT1D receptors, and an inhibitor at the 5-HT transporter (SERT). Thus, like SSRIs, vortioxetine
inhibits the reuptake of serotonin in synapses. But unlike SSRIs, it also differentially modulates
the above 5-HT receptors. Of particular importance among these mechanisms is 5-HT3 receptor
antagonism, which has emerged as a key mechanism (Pehrson & Sanchez, 2014). 5-HT3 receptors
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are excitatory ion channels that are exclusively expressed by a subset of non-fast spiking inhibitory
GABAergic cells (Pehrson & Sanchez, 2014), and are commonly expressed in cognition relevant
regions such as the frontal cortex and hippocampus (Dale et al, 2016; Pehrson et al, 2016).
Antagonism of these receptors reduces GABAergic inhibitory influences on pyramidal neurons,
leading to increases in firing rates (Riga et al, 2016). Interestingly, nonclinical pharmacology
research in rodents demonstrated that vortioxetine improves some aspects of cognitive function,
such as object recognition memory, at does in which it selectively antagonizes 5-HT3 receptors
(du Jardin et al, 2014). These data suggest that increased glutamate neurotransmission may be a
relevant strategy for improving cognition in depression.

Glutamate Neurotransmission
Glutamate, the primary excitatory neurotransmitter in the central nervous system,
contributes to the function of most synapses in the brain and binds to two families of receptors:
ionotropic and metabotropic receptors. Ionotropic glutamate receptors are comprised of ligandgated ion channels that respond directly to glutamate, and include receptors such as N-methyl-Daspartate (NMDA), -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and
kainate (Reiner & Levitz, 2018). Metabotropic glutamate receptors (mGluRs) consist of 8 subunits,
mGluR1-mGluR8, divided into three groups based on sequence homology and function. Group I
(mGluR1 and mGluR5) are stimulatory receptors located on postsynaptic neurons and are Gq/11coupled. Group II (mGluR2-3) and Group III (mGluR4, mGluR6-8) receptors are inhibitory
receptors located on both presynaptic and postsynaptic neurons and are Gi/Go-coupled (Hillhouse
& Porter, 2015).
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NMDA receptors are tetramers consisting of two GluN1 subunits and two GluN2 subunits.
NMDAR signaling is complex in that it is ligand-gated as well as voltage-gated (Reiner & Levitz,
2018), and can therefore be thought of as a synaptic coincidence detector. Glutamate binds to the
GluN2 subunits while the amino acid glycine binds to the GluN1 subunits. Both of these ligands
are required to bind to their subunits simultaneously in order to allow proper function of the
NMDA receptor. However, NMDARs will only become active when both transmitters are bound
and sufficient membrane depolarization to expel Mg2+ ions has been achieved. Activated
NMDARs allow Ca2+ ions to enter the cell, which has a variety of important effects that will be
described below.
AMPA receptors (GluAs) are stimulatory ionotropic receptors directly activated by the
binding of glutamate, resulting in rapid depolarization of the cell. Glutamate activity at AMPA
receptors (AMPARs) is crucial for depolarizing NMDA receptors (NMDARs) in order to unblock
NMDA channels and allow for an influx of Ca2+ and Na+ ions. In addition to AMPARs, the Group
I mGlu5 receptors have also been found to trigger activation of NMDARs. Whereas AMPARs
directly depolarize NMDARs, mGluR5 indirectly increases the chances of NMDA channels
opening by increasing NMDAR phosphorylation (Holly, LaCrosse, & Hillhouse, 2014).

Relevance of Glutamatergic Neurotransmission to MDD
Dysfunction of the glutamate receptor system has been linked to the pathophysiology of
depression (Holly, LaCrosse, & Hillhouse, 2014). Individuals with depression have consistently
shown elevated levels of glutamate in the prefrontal cortex, a region of the brain that is notably
important for cognitive function, and significantly reduced levels of glutamate in regions such as
the hippocampus and amygdala. These fluctuating glutamate levels may result from malfunction
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of the mGluR5 proteins (Holly, LaCrosse, & Hillhouse, 2014). Overall, the whole brain
distribution volume of mGluR5 in depressed patients is 8.8% lower than in healthy patients due to
a reduction in mGluR5 expression, and mGluR5 expression in the hippocampus is negatively
correlated with depressive symptoms, which may contribute to the memory dysfunctions observed
in depression.

Ketamine as a Flawed Breakthrough Antidepressant
Glutamate neurotransmission was further linked to depression pathology after a pioneering
clinical study that linked ketamine, a noncompetitive NMDAR antagonist among other actions, to
rapid antidepressant effects in treatment-resistant patients (Berman et al, 2000). In this placebocontrolled study, a single low dose of ketamine (0.5 mg/kg delivered intravenously, i.v.) resulted
in significantly improved depression scores 72 hours later on the Hamilton Depression Rating
Scale (HAM-D), suggesting a possible role of glutamatergic activity at NMDARs in depression.
Ketamine has also been used to resolve suicidal ideation in treatment-resistant depressed patients
at low i.v. doses of 0.5 mg/kg (Diaz-Granados et al, 2010; Price et al, 2014). In emergency use,
Diaz-Granados and colleagues (2010) found ketamine to reduce self-reported suicidal ideation
starting at 40 minutes post-administration for up to 4 hours post-administration. Price and
colleagues (2014) observed similar results in the first place-controlled study of ketamine’s effects
on suicidal ideation, with sustained reductions in both explicit and implicit suicidal ideation 24
hours post-administration. There is also work suggesting that ketamine (0.5 mg/kg, i.v.) can
prolong its antidepressant-like effects for as long as 7 days post-infusion (Zarate et al, 2006).
Compared to placebo, a single low dose of ketamine has improved depression scores on the HAMD 24 hours post-infusion for treatment-resistant patients, with a large effect size of 1.46.
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Additionally, 1/3 of these patients sustained reduced depressive symptoms at 7 days post-infusion,
with a moderate effect size of 0.68.
However, despite its antidepressant effects 24 hours post-administration, ketamine is
known to have undesirable psychotomimetic side effects shortly after administration (Chan et al,
2012; Pitsikas, Bouldtadakis, & Sakellaridis, 2008; Lapidus et al, 2014). The hypoactivation of
NMDARs caused by ketamine leads to acute cognitive dysfunction as a result of reduced glutamate
neurotransmission. Such impairments include poor recognition and spatial memory retention,
severe dissociation, and motor hyperactivity, making ketamine an impractical drug of choice for
depression treatment.
Though ketamine’s mechanisms of action are not fully understood, NMDA antagonism
was initially thought to be responsible for its antidepressant effects after the drug had left the
system. However, other NMDAR antagonists such as dizocilpine (MK-801) and phencyclidine
(PCP) do not display sustained antidepressant effects, leading to the theory that there may be other
factors at play that cause ketamine’s antidepressant effects (Aleksandrova et al, 2017). One such
theory is ketamine’s effects on AMPA receptors. Preclinical neuropharmacology research suggests
that ketamine’s antidepressant properties are induced by increased AMPA receptor-mediated
glutamate neurotransmission. In the rat forced swim test (FST), rats dosed with ketamine displayed
lower immobility time in the water than rats dosed with saline, signifying an antidepressant-like
effect (Zhou et al, 2014). These rats also displayed higher brain-derived neurotrophic factor
(BDNF) expression, which is associated with enhancing AMPA expression, in the hippocampus
and prefrontal cortex, measured via Western blot. Then, pretreatment with the AMPAR antagonist
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2, 3-dione (NBQX) led to increased
immobility times after ketamine injection. Thus, the antagonism of AMPARs by NBQX impairs
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ketamine’s ability to be effective as an antidepressant (Zhou et al, 2014; Li et al, 2010). For this
reason, enhanced AMPA expression is deemed essential for ketamine’s antidepressant action.
Compared to other NMDAR antagonists, ketamine is unique in that it can enhance
expression of AMPA receptors 24 hours after administration, and there is evidence tying this
increase in AMPA receptor expression to ketamine’s antidepressant properties. Long-term
exposure to MK-801 actually leads to a decrease in the amplitude of AMPA-mediated excitatory
post-synaptic potentials (EPSPs) in interneurons, and prolonged treatment with PCP reduces the
expression of GluA2 and GluA3 receptors in the prefrontal cortex of rats (Wang & Gao, 2012;
Barbon et al, 2007). As of yet, no study has been able to link PCP or MK-801 to enhanced AMPA
expression, making it unlikely that noncompetitive NMDA receptor inhibition is relevant for
ketamine’s antidepressant activity.
Ketamine’s immediate psychotomimetic effects (hyperactivity, significant dissociative
properties, and psychosis-like symptoms parallel to schizophrenia) and its potential for narcotic
abuse are undesirable and impractical for widespread use as a treatment for the cognitive deficits
in depression. These adverse effects are a direct result of NMDA receptor inhibition (Keilhoff et
al, 2004). This means that a solution to this issue would be to achieve the same increases in AMPA
expression as ketamine without inhibiting the NMDA channel. Zanos et al. (2016) investigated the
relationship between ketamine and two of its metabolites, the (2S,6S)-hydroxynorketamine and
(2R,6R)-hydroxynorketamine (HNK) enantiomers, as well as their effects on glutamate receptor
activity at NMDA and AMPA channels. First, these authors established that the metabolism of
ketamine into its (S,R)-HNK enantiomers is required for sustained behavioral antidepressant-like
effects 24 hours post-administration. This idea was confirmed using rats in the forced swim test
(FST), which assesses behavior in terms of passive (i.e. immobility) or active (i.e. swimming and
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climbing) coping. There was a much more pronounced influence of (2R,6R)-HNK on active
response in the FST than of (2S,6S)-HNK, despite the fact that it is less abundant in the brain and
has less affinity for NMDAR inhibition than (2S,6S)-HNK (affinity for NMDARs is presented in
Table 1). Not only does (2R,6R)-HNK have less affinity for inhibiting NMDARs, but it also
produces an increase in AMPA receptor expression 24 hours post-administration in the CA1 region
of the hippocampus (Zanos et al, 2016). Similar to ketamine, when AMPA receptor activity is
blocked with NBQX, (2R,6R)-HNK is no longer able to produce the advantageous behavioral
response in the FST 24 hours post-administration. These data further support the requirement of
AMPA receptor expression for fast antidepressant-like activity, as well as its requirement in
ketamine and (2R,6R)-HNK’s mechanisms of action. As an added measure, (2R,6R)-HNK does
not result in the acute motor hyperactivity, the lack of motor coordination, or the abuse potential
that ketamine does, making it a more practical and a safer alternative for the possible treatment of
cognitive dysfunction (Zanos et al, 2016). As of yet, there is little evidence to suggest that (2R,6R)HNK leads to acute impairment, with the consensus being that its low affinity for NMDAR
antagonism allows it to bypass these adverse side effects (Morris et al, 2017; Zanos et al, 2016).
Still, the breadth of research on (2R,6R)-HNK’s acute effects remains limited, and more work is
needed to assess (2R,6R)-HNK’s effects in a variety of cognitive tasks.

Synaptic Plasticity in Depression
The popular view of the root of depression is that there is a chemical imbalance of
neurotransmitters in the brain, namely serotonin and noradrenaline, that lead to behavioral and
emotional disturbances (Castrén, 2005). While this may be true, an alternate explanation is that
there is a problem of communication between neural networks that results in deficits in cognitive
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flexibility (Castrén, 2005; Normann et al, 2007). Evidence supporting the idea that chemical
imbalances are not the sole cause of depression comes from Booij et al. (2003)’s review on the
temporary suppression of monoamine function through tryptophan depletion. In both healthy and
depressed subjects, serotonin depletion had mild to no effects on mood, suggesting that there is
not a simple link between chemical concentrations and depression. In fact, chronic exposure to
SSRIs and SNRIs itself results in serotonin depletion due to homeostatic compensation for the
increased synaptic 5-HT concentrations caused by SSRI/SNRIs (Strüder & Weicker, 2001). Thus,
depression may instead result from deficiencies in synaptic plasticity.
Synaptic plasticity refers to the brain’s ability to modify the strength of communication
between different cells and neural networks. Synaptic plasticity is commonly studied through a
mechanism called long-term potentiation (LTP), which is characterized by increases in the
magnitude or frequency of excitatory post-synaptic potentials (EPSPs) in response to stimuli
(Bashir & Collingridge, 1992; Kalat, 2015). Increased or enhanced LTP is a measure of greater
synaptic plasticity. LTP is most extensively studied in the hippocampus of both animals and
humans, and is associated with learning and memory processes (Bashir & Collingridge, 1992).
The rapid increase in EPSPs primes postsynaptic neurons to be more receptive of incoming stimuli
potentials, hence the association with aiding in learning. According to Normann and colleagues
(2007), this process is disrupted in depression. Normann et al. (2007) studied differences in
synaptic plasticity by evoking excitatory potentials in the visual cortex of healthy subjects and
depressed patients, all of whom were on one or more antidepressants at the time. Compared to
healthy individuals, depressed patients exhibited a significantly reduced response in plasticity in
response to visual stimuli. In order to rule out the effect of medication, healthy subjects were
treated with SSRIs for 3 weeks, resulting in increased synaptic plasticity response compared to
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controls. Not only does this suggest that antidepressants partially aid in repairing neural network
function, it may also suggest that depression is related to maladaptive synaptic plasticity. The
experience of prolonged stress in depressed individuals is linked to excessive glucocorticoid
hormone release via the hypothalamic-pituitary-adrenal (HPA) axis, which in turn triggers
elevated synaptic glutamate release in pyramidal neurons. Excessive glutamate transmission alters
healthy plasticity events by reducing dendritic density and arborization (Musazzi, Racagni, &
Popoli, 2011). In rodents, stress-induced simplifications of the dendritic arbor in the hippocampus
have been correlated with cognitive impairment in spatial memory and attention-shifting tasks. In
the rodent hippocampus, this reduction in dendritic arborization has been found to be reversible
with the use of antidepressants, suggesting a possible target for treatment of depression.
Individuals with depression have significantly reduced hippocampal volume (Sheline et al, 1996;
Musazzi, Racagni, & Popoli, 2011), which may play a role in deficits in learning, memory, and
LTP. The length and severity of one’s depression predicts the extent of hippocampal degeneration.
Healthy LTP function is thought to depend on proper functioning of the two glutamatergic
ionotropic receptors, AMPA and NMDA (Bashir & Collingridge, 1992; Javitt, 2007). LTP is
triggered through the coordinated relationship between AMPARs and NMDARs. When glutamate
binds to AMPARs, a rapid depolarization effect aids in the activation of NMDARs. Glutamate and
glycine must also be bound to their respective NMDA subunits in order to allow proper
depolarization, which then expels the voltage-gating Mg2+ ions that block NMDA channels. Once
the channel has opened, Ca2+ ions flood into the cell. Higher levels of calcium signaling are thought
to be linked to LTP (Evans & Blackwell, 2015). Calcium can alter the activity of a number of
different intracellular signaling molecules, and the specific molecule that it binds to determines its
function. When cell concentrations of calcium are high, calcium has a higher affinity for binding
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to calcium/calmodulin-dependent protein kinase II, or CaMKII, than it does for binding to
calcineurin, another calcium-binding protein (Evans & Blackwell, 2015). Binding to CaMKII
leads to various phosphorylation events that underlie LTP, and the high concentration of cellular
calcium that is needed to induce LTP derives primarily from the activation of NMDARs. Low
levels of cellular calcium lead to an affinity for the calcium-binding protein calcineurin, which
results in dephosphorylation events that precede long-term depression (LTD). LTD, in contrast to
LTP, refers to the weakening of synaptic communication.
As discussed earlier, NMDAR antagonism is not ideal for cognition due to the
psychotomimetic side effects that occur shortly after receptor blockage, a result of glutamatergic
dysfunction (Keilhoff et al, 2004). In some instances, antagonism of NMDARs has resulted in
impairments in LTP. The competitive NMDA antagonist D-2-amino-5phosphonopentanoate (DAP5) impairs spatial memory learning in the rat open-field water maze task, while also impairing
evoked LTP in the hippocampus (Davis, Butcher, & Morris, 1992). AP5-induced performance
impairments were correlated to impaired LTP, since no dose of AP5 was able to impair LTP
without affecting spatial memory performance. Furthermore, the noncompetitive NMDAR
antagonists memantine and MK-801 also impair LTP induction in the CA1 region of the
hippocampus, with MK-801 being more potent in its antagonism (Frankiewicz et al, 1996). These
findings suggest a link between healthy LTP mechanisms and NMDA receptor function.
A number of studies have also observed increases in AMPAR expression in conjunction
with enhanced LTP. In a 1992 study by Tocco and colleagues, LTP was induced through electrode
implantation and electrical stimulation to evoke EPSPs in the rat hippocampus. They demonstrated
that LTP is linked to AMPAR activity through autoradiographs that depicted significantly higher
levels of AMPA receptor expression in rats who exhibited LTP compared to rats who did not
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exhibit LTP in the hippocampus. The same study also established a link between LTP and the
AMPA/NMDA pathway by investigating the generation of LTP after administration of ketamine.
Ketamine (30 mg/kg delivered intraperitoneally 2 hours prior to decapitation and freezing) blocked
NMDA activity, which consequently hindered the process of LTP and led to low levels of AMPA
receptor expression measured via autoradiography.
AMPA receptor activity has also been linked to behavioral displays of memory
performance. Bonini and colleagues (2003) administered the AMPA receptor antagonist 6-cyano7-nitroquinoxaline-2,3-dione (CNQX) directly into various regions of rat brains, including the
CA1 hippocampal subregion, and examined its effects on memory consolidation in an avoidance
task. In this task, rats were placed on the top level of a platform and were measured on latency
time to step down from the platform, at which point they would receive a foot shock. During
training, stepping down from the platform forms a negative memory of foot shock, which normally
increases latency to step down in the subsequent testing trials. Rats who received CNQX
administration in the CA1 hippocampal subregion displayed significantly lower latency to step
down than control rats at a number of timepoints up to 6 hours post-administration (Bonini et al,
2003). These data suggest that antagonism of AMPARs by CNQX prevented memory formation
of the foot-shock.
Further, hippocampal infusion of CNQX impairs retrieval memory in a digging task
compared to controls (Bast, da Silva, and Morris, 2005). In this task, rats were trained to obtain a
reward by digging in a sand cup placed in a specific location in an open field. During testing,
memory for the location of the food reward was assessed by placing multiple sand cups in the
field, with the food reward remaining in the original trained location. Blocking AMPAR activation
with CNQX leads to longer times spent digging in the wrong locations and less time spent digging
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in the correct location compared to controls, indicating a deficit in retrieval memory due to
blockade of AMPA-mediated LTP processes. Taken together, these data suggest that AMPA
receptor antagonism reliably impairs memory performance.
In cognitive impairment models in rodents, positive allosteric modulators (PAMs) of
AMPARs have been used to demonstrate the importance of AMPA expression for healthy
cognition and memory. A positive allosteric modulator binds to receptors and changes the structure
of the receptor to enhance its response to stimuli. S-18986, a selective PAM of AMPA receptors,
has been used to treat memory impairments induced in the lab via cholinergic transmission
blockers in a variety of memory tasks (Bernard et al, 2010). S-18986 is able to restore induced
learning and memory impairments in spatial memory, procedural memory, and recognition
memory tasks in rodents as a result of its action at AMPA receptors (Rosi et al, 2004; Lebrun,
Pilliere, & Lestage, 2000). AMPAkines, which are compounds that slow the rate of AMPA
receptor deactivation therefore prolonging excitatory postsynaptic potential (EPSP) duration, are
associated with enhancements in memory in both rodents and humans (Hampson, Rogers, Lynch,
& Deadwyler, 1998). The AMPAkine CX516 has been shown to enhance hippocampal-dependent
spatial short-term memory in rodents using the delayed nonmatch to sample (DNMS) task.
Compared to controls, rodents injected with CX516 displayed significantly higher correct
responses across all intertrial delays, ranging from 1-40 seconds (Hampson et al, 1998). In healthy
adult humans, CX516 facilitates enhancements in spatial (computerized maze) and recognition
(odor smells) memory compared to placebo (Ingvar et al, 1997). Similarly, the AMPAkine
farampator has shown significant short-term memory enhancements compared to placebo using
the symbol-digit recall test (SDRT) in healthy elderly adults (Wezenberg, Verkes, Ruigt, Hulstijn,
& Sabbe, 2007). These data on the effects of AMPAkines and AMPA PAMs in both normal and
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chronic stress paradigms strengthen the relationship between AMPAR activation and enhancement
of LTP and memory processes.
Brain-derived neurotropic factor (BDNF) is another essential protein for LTP, cell growth,
and synaptic plasticity. BDNF promotes dendritic outgrowth, which as described above facilitates
LTP induction. Treatment with SSRIs routinely increases BDNF (Sangkuhl, Klein, & Altman,
2009), and increased BDNF is sufficient to induce LTP in the hippocampus on its own. When
NMDA receptor activity is suppressed via antagonism, synaptic potentials in the CA1 hippocampal
subregion are potentiated through BDNF expression, resulting in LTP (Ying et al, 2002;
Messaoudi et al, 2002). Increases in BDNF expression also enhance expression of the AMPA
subunits GluA1 and GluA2, further setting the stage for augmented LTP processes (Nosyreva et
al, 2013). Interestingly, blockade of the BDNF receptor tropomyosin receptor kinase B (TrkB)
impairs ketamine’s ability to have its long-lasting antidepressant-like effects (Lodge et al, 2012),
which supports the idea that when NMDARs are blocked by ketamine, BDNF is responsible for
mediating enhanced LTP processes via AMPA enhancements—all of which is obstructed when
TrkB is blocked.
The AMPAkine CX929 is known to upregulate BDNF expression (Simmons et al, 2009;
Seese et al, 2019). Upregulation of BDNF via AMPAkines has been found to lead to enhancements
in hippocampal-dependent memory in rodents. Twice daily injections of the AMPAkine CX929
for 4 consecutive days in mice leads to greater phosphorylation of TrkB in the CA1 hippocampal
subregion compared to controls, which in turn triggers higher BDNF expression (Seese et al,
2019). This upregulation of BDNF has also been behaviorally linked to restoring induced spatial
memory impairments in knockout mice using the Object Placement (OP) task described below.
Mice injected with CX929 twice-daily for 4 consecutive days display a complete restoration of
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spatial memory that matches memory performance of controls (Seese et al, 2019). Injection of
CX929 also restores deficits in LTP seen in aged mice. Simmons and colleagues (2009) measured
EPSPs in response to theta burst stimulation (TBS) in hippocampal slices of aged mice injected
with either vehicle or CX929. Treatment with the AMPAkine CX929 results in a restoration of
EPSPs, a measure of LTP, that has naturally decayed with age in these mice. Therefore, it can be
concluded from these data that AMPAkines have the ability to enhance LTP processes, and these
enhancements are observable behaviorally in spatial memory performance. Though increases in
AMPA expression are believed to be beneficial for cognitive function, there is yet to be a
systematic investigation of the effects of AMPAR activity on LTP processes.

Ketamine’s Effects on LTP and Cognitive Performance
Of particular interest is ketamine’s effect on memory and LTP expression in the
hippocampus. The hippocampus is widely known to be important for the encoding and retrieval of
explicit memories, recognition memory (which also involves expanded circuitry that includes the
perirhinal cortex), and especially spatial memory (Bird & Burgess, 2008; Broadbent, Squire, &
Clark, 2004; Barker & Warburton, 2011). As mentioned previously, the hypoactivation of
NMDARs caused by ketamine leads to acute impairments in LTP observable as cognitive
dysfunction that includes memory impairment. Cognitive function in terms of recognition and
spatial memory is commonly studied in rodents using the novel object recognition (OR) task and
the novel object placement (OP) task, respectively (Pitsikas, Bouldtadakis, & Sakellaridis, 2008;
Assini, Duzzioni, & Takahashi, 2009; Barker & Warburton, 2011). Both tasks involve two testing
sessions, an information trial (IT) and a retention trial (RT), separated by an inter-trial interval. In
the information trial, two identical objects are placed into a testing arena in specific locations. The
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arena for an OP task also requires that spatial cues be placed on the walls of the arena in order to
ensure that the rat is orienting themselves to the arena and to the specific location of objects relative
to the arena. During the IT phase, rats are placed into the arena with the spatial cues and objects
and are allowed to explore the objects undisturbed. After an inter-trial interval, one of the objects
is either replaced with a new object (OR task) or one of the objects is moved to a novel location in
the arena (OP task). An appropriate response in these tasks would be for the rat to spend more time
exploring (i.e. sniffing, touching, or approaching) the novel object (OR) or the object in the novel
location (OP) compared to the original object or the object in the original location. These tasks
combined with the administration of drugs that either enhance or inhibit LTP expression are used
to explore the relationship between LTP function and rodent cognition and behavior.
For instance, in their 2008 study, Pitsikas and colleagues tested rats on their recognition
and spatial memory using the OR task and the OP task respectively, 20-60 minutes after
intraperitoneal (i.p.) ketamine injection. At this acute time point, ketamine (1 mg/kg and 3 mg/kg,
but not 0.3 mg/kg) significantly impaired both the encoding and retrieval processes in these tasks
as expected. Thus, acute ketamine administration is associated with impairments in memory
performance in these tasks that are probably related to its antagonist properties at the
noncompetitive NMDA receptor site.
As discussed above, a number of studies demonstrate that ketamine can have
antidepressant-like effects 24 hours post-administration, a time-point at which the drug is no longer
detectable in the body (Patton et al, 2017; Graef et al, 2015; Jett et al, 2015; Parades, Silva, &
Morilak, 2018; Nosyreva et al, 2013). These antidepressant-like effects have focused on correcting
deficits in reversal learning, deficits in coping, and deficits in synaptic plasticity (such as LTP
expression). Patton et al. (2017) used the attentional set-shifting test to determine whether
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ketamine could correct the learning deficits that occur after rats undergo 2 weeks of chronic
intermittent cold stress. In the attentional set-shifting test, rats are required to differentiate between
two cups to find a potential food reward on the basis of two dimensions. One dimension is the odor
applied to the rim of the cups, and the other dimension is the medium that fills the pot (i.e. sand,
etc.). In the first phase, rats find the reward in the cup with an odor applied to the rim vs. the cup
without any odors. In the second phase, a distractor cue (e.g., sand) is introduced alongside the
odor cue. When rats undergo 2 weeks of chronic stress treatment, they are slower to learn that they
must shift their attention from the odor cue to the digging material cue in order to continue
receiving the reward. However, 10 mg/kg of ketamine administered 24 hours prior to testing
corrected this learning deficit in stressed rats compared to stressed drug-free rats. Jett et al. (2015)
also demonstrated that 10 mg/kg of ketamine protected rats against maladaptive coping strategies
in the shock probe defensive burying (SPDB) test. While stressed drug-free rats cope with being
shocked by a probe by remaining immobile (passive, helpless coping), rats who were dosed with
ketamine 24 hours prior to testing take an active coping approach of burying the shock probe.
Since LTP is a measure of synaptic plasticity that is putatively related to memory function,
an increase in hippocampal LTP implies improved performance on spatial memory tasks such as
the OP task. A recent investigation evaluated the effects of ketamine on high-frequency stimulation
(HFS)-induced LTP in the CA1 region of hippocampal slices, measured as the slope of evoked
EPSP responses (Graef et al, 2015). When administered 20 minutes prior to testing, ketamine (10
M bath-applied) impaired LTP compared to controls. However, injected 24 hours prior to HFS
at 30 mg/kg, evoked EPSP responses significantly exceeded those exhibited by control rats,
suggesting enhanced capacity for synaptic plasticity in the hippocampus. This implies that
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ketamine tackles cognitive deficits via AMPA-mediated LTP enhancement 24 hours after
administration as opposed to antidepressants currently on the market that take weeks to take effect.
Links between the hippocampus and its necessity for recognition memory and spatial
memory have been established by creating bilateral lesions in the dorsal and ventral hippocampi
of rodents (Broadbent, Squire, & Clark, 2004; Barker & Warburton, 2011; Jablonski et al, 2013).
Of particular importance is a study by Barker & Warburton (2011) that investigated the
relationship between the hippocampus and spatial memory in rats using the novel object placement
(OP) task. In this task, rats were presented with two identical objects at two ends of an arena during
the IT phase. After an intertrial interval, they were once again presented with the same two objects
with the exception that one object had been moved to a novel location in the arena. The supposition
is that the memory of spatial cues on the walls of the arena should allow rats to recognize that one
object is in a novel location, which is behaviorally demonstrated by increased exploration of the
object in the novel location compared to the non-moved object in the RT phase of the task. Spatial
memory performance was quantified as a discrimination ratio, which was the absolute difference
between the time spent exploring the novel placement object and the unmoved object divided by
the total amount of time spent exploring both objects (Barker & Warburton, 2011). When rats are
given bilateral dorsal hippocampal (HPC) lesions (ranging from 2.1 mm to 6.0 mm posterior to
Bregma), performance in the OP task is significantly impaired compared to comparison groups
with bilateral lesions in the perirhinal cortex (PRH), the medial prefrontal cortex (mPFC), and
controls (discrimination ratio ± SEM: HPC, -0.06 ± 0.07; PRH, 0.33 ± 0.06; mPFC, 0.29 ± 0.06;
controls, 0.39 ± 0.05; Barker & Warburton, 2011). Neither the PRH or mPFC lesion groups
differed from the controls. In order to reach the discrimination ratio achieved by the controls, rats
would need to spend almost double the amount of time exploring one object over the other, which
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can be assumed to be the object with the novel placement. In order to reach the discrimination ratio
achieved by the HPC lesion group, however, rats would have to spend roughly the same amount
of time exploring both objects, signifying no memory of either object’s location having been
moved. This study solidifies the relationship between spatial memory and the hippocampus.

The Current Study: Rationale and Hypotheses
The current study investigates the ability of (2R,6R)-HNK to enhance AMPA receptor
expression in the dorsal hippocampus of rats. Since an intact hippocampus was previously
determined to be a requirement for the development of spatial memory (Barker & Warburton,
2011), rats dosed with (2R,6R)-HNK will also be tested on changes in spatial memory in the novel
object placement (OP) task. There are two hypotheses in this study:
1. (2R,6R)-HNK administration will cause an increase in hippocampal AMPA receptor
expression 24 hours post-injection.
2. (2R,6R)-HNK administration will cause an improvement in performance in the rat novel
object placement task.
Rationale:
Graef et al. (2015) show that ketamine enhances synaptic plasticity via increased LTP in
the CA1 region of the hippocampus 24 hours post-administration. Increases in LTP are associated
with increased AMPAR expression as measured by autoradiographic binding (Tocco et al, 1992).
Due to evidence suggesting ketamine may rely on its metabolism into (2R,6R)-HNK to exert its
antidepressant-like effects, direct (2R,6R)-HNK administration should result in enhanced AMPA
receptor expression. Therefore, it is hypothesized that (2R,6R)-HNK will enhance LTP 24 hours
post-administration, quantifiable via increased hippocampal AMPA receptor expression compared
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to saline. Secondly, because of the expected increases in LTP and AMPA expression in the
hippocampus, it is hypothesized that (2R,6R)-HNK will result in an enhancement of cognitive
function (i.e. spatial memory) 24 hours post-administration compared to saline in the
hippocampally-dependent OP task. In contrast to ketamine, acute administration of (2R,6R)-HNK
does not result in psychotomimetic side effects. There is also little work examining (2R,6R)HNK’s effects on cognition, therefore investigation of (2R,6R)-HNK’s behavioral and biological
effects is a novel effort. Our a priori methods and hypotheses were preregistered with
aspredicted.org, a copy of which is attached in Appendix A.

Methods
Subjects. Subjects consisted of 80 adult male Long Evans rats (Envigo, Indianapolis, IN,
aged 7-8 weeks at delivery). Twenty of these rats were used for AMPA receptor expression
analysis, while the remaining 60 were used to examine spatial memory in the OP task. Rats were
pair-housed in a temperature and humidity-controlled room with ad libitum access to food and
water in the home cage. Four rats were separated due to fighting. Separation of animals did not
result in any behavioral or biological data abnormalities. Animals were kept to a 12-hour light and
dark cycle (lights on at 7 a.m.). All procedures were conducted during the light phase of the cycle.
All procedures were in accordance with the Guide to the Care and Use of Laboratory Animals,
and were approved by the Montclair State University Institutional Animal Care and Use
Committee prior to the start of experiments (IACUC protocol 2017-041).
Behavioral Apparatus. Behavioral testing was carried out in a square, blue Plexiglas
arena of the dimensions 62.2 cm x 62.2 cm x 41.3 cm (Maze Engineers, Boston, MA). Spatial cues
consisting of black and white shapes were placed on each wall of the arena on laminated 21.6 cm
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x 27.9 cm paper. The arena was placed in the middle of four black welders’ curtains to block out
distal spatial cues. An overhead camera was used to record trials and the videos were used to
collect exploration time and locomotor data for subsequent analyses. The objects used in all trials
were white plastic bottles with narrow necks (Figure 1). Bottles were filled halfway with sterilized
sand in order to minimize the chance of being knocked over or moved while the animals explored.
Drugs and Chemicals. (2R,6R)-hydroxynorketamine (HNK) was purchased from SigmaMillipore (Burlington, MA), while 6-nitro-2,3-dioxo-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7sulfonamide (NBQX) was purchased from Tocris Bioscience (Bristol, UK). [ 3H] α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) was purchased from Perkin-Elmer
(Waltham, MA).
Injections. All animals were randomly assigned to receive vehicle or 1 mg/kg, 3 mg/kg,
or 10 mg/kg HNK intraperitoneally (i.p.) at 2 mL/kg injection volume 24 hours prior to testing
(see methods below). (2R,6R)-HNK was dissolved in saline at a pH of 7.0 and was syringe filtered
for sterility prior to injection. Doses refer to the mass of the free base rather than the salt.
Behavioral and Biological Testing Procedures. Upon arriving in the lab, all animals were
allowed one week to acclimate to their environment without disruption. Immediately following
acclimation, each rat was handled for five consecutive days for 5-minute sessions. After
completion of handling training, all animals underwent four consecutive days of habituation to the
testing arena. A typical day of habituation to the arena consisted of each rat being placed into the
empty arena with spatial cues for 10 minutes per day. During each 10-minute habituation session,
the rat was allowed to explore the arena undisturbed. The day after the final habituation session,
each animal received an injection of vehicle or (2R,6R)-HNK. For each animal, the injection was
delivered at a predetermined time of day in order to ensure a 24-hour delay between injection and
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the start of behavioral or biological testing (refer to Table 2 for randomized dose groups and
schedule of injections).
Novel Object Placement (OP) Task. Animals in the behavioral testing group (N=60)
began the information trial (IT) of the OP task exactly 24 hours post-injection. During the
information trial, each animal was placed into the arena containing two white plastic bottles and
was allowed to explore the objects for 5 minutes. The objects were placed 10 cm away from each
wall of the two lower corners of the arena. After a 10-minute intertrial interval (ITI), each animal
began the retention trial (RT) of the OP task. During this trial, one object was moved to a novel
location in the field (see Figure 2 for object layouts). The location and identity of the object in the
novel location (i.e. left vs. right) during the retention trial was counterbalanced across dose groups
in a block-wise fashion (Table 2). Figure 3 presents a timeline of events for both the behavioral
and biological testing groups.
Ex Vivo Autoradiography of [3H] AMPA. The effects of (2R,6R)-HNK administration
on AMPA receptor expression was investigated using ex vivo autoradiography of [3H] AMPA in
20 animals. Injection of (2R,6R)-HNK or vehicle were conducted as described above.
Tissue Preparation. 24 hours after acute treatment with vehicle or (2R,6R)-HNK,
behaviorally-naïve animals were anesthetized using CO 2 and killed by decapitation using a
sharpened guillotine. Brains were quickly dissected from the skull, flash-frozen on dry ice, and
stored at -20oC until use. Forty replicate 15 µm thick coronal tissue sections were collected per
brain using a cryostat (ThermoFisher, Waltham, MA) from a region of the brain ranging from 2.40
mm to 3.0 mm posterior to Bregma (Paxinos and Watson, 1982), which is a region of the brain
including the dorsal hippocampus. This region was chosen based on lesion study evidence that it
is critical for the performance of the OP task (Barker & Warburton, 2011). Tissue slices were thaw
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mounted on glass microscope slides (SuperFrost Plus, Fisher Scientific, Hampton, NH) and stored
in slide boxes with desiccant pellets at -20oC until use.
Binding Procedures. On the day of the binding experiment, slide boxes were equilibrated
to room temperature (RT) prior to opening in order to ensure that no frost accumulated on tissue
slices. Slides were preincubated for 20 minutes at 4oC in a preincubation buffer consisting of 30
mM Tris HCl and 2.5 mM CaCl2 (pH = 7.4). Subsequently, slides were dried in a vacuum
desiccator at RT prior to incubation in an assay buffer consisting of 30 mM Tris HCl, 2.5 mM
CaCl2, 100 mM KSCN, and 10 nM [3H] AMPA at RT for 60 minutes. Nonspecific binding was
determined in a subset of slides by adding 10 µM of the AMPA receptor orthosteric antagonist
NBQX (Ki = 60 nM; Ohmori et al, 1994). After binding was completed, slides were washed three
times in cold preincubation buffer (4oC) for 20 seconds each. Slides were dried in a vacuum
desiccator overnight before being apposed to a tritium-sensitive phosphor plate (Fuji imaging
plate, GE Healthcare, Pittsburgh, PA) for 7 days. Finally, an autoradiographic image was taken
using a Typhoon Biomolecular Imager (GE Healthcare, Pittsburgh, PA).

Data Analysis and Statistical Methods
AMPA Receptor Binding. Optical intensity values were quantified from the dorsal
hippocampus using ImageQuant TL software (GE Healthcare, Pittsburgh, PA). The primary
dependent measure for AMPA receptor binding studies was specific bound radioactivity. Bound
radioactivity values for tissue were interpolated from optical intensity values by interpolating from
the standard curve using a method described previously (Pehrson et al, 2018).
Novel Object Placement Task. The primary dependent variable in the behavioral task was
each animal’s preference for the bottle placed in the novel location during the retention trial of the
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OP task. A preference score was calculated for each animal as follows: (amount of time spent
exploring the object in the novel location)/(total amount of time spent exploring both objects) x
100. Exploration of an object was defined as facing the object with < 2cm distance, and interacting
with or sniffing the object. Sitting next to or on top of the object was not considered exploration.
Exploration times were assessed by two independent researchers using the video recordings
obtained during data collection. Both researchers were blind to the dose conditions while coding
exploration times. Scores from both researchers were used to establish interrater reliability. Two
secondary dependent measures were also explored: total exploration times (s) and total distance
(cm) travelled during the retention trial of the OP task. Distance travelled and other locomotor
activity was collected via SMART video-tracking software (Harvard Apparatus, Holliston, MA).
Statistical Analysis. Tests for normality (Lilliefors) and homogeneity of variance
(Levene’s test) were conducted on the residuals of each dependent variable. This was done to allow
us to conduct a single normality test for each dependent variable to lower the chance of inflated
outlier detection. In cases where data was normally distributed, a one-way between-subjects
ANOVA was conducted, followed where appropriate by Tukey-Kramer post hoc tests. In cases
where data was not normally distributed, a Kruskal Wallis nonparametric ANOVA followed where
appropriate with Wilcoxon Ranked Sign post hoc tests were used. Alpha levels were set at 0.05
for all inferential analyses. All analyses were conducted in R, and R codes of behavioral and
biological analyses are attached below (R Core Team, 2020). Data are presented as mean ± SEM.
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Results
A priori-defined Primary Analyses:
The Effect of (2R,6R)-HNK on Hippocampal AMPA Receptor Binding. The primary
biological dependent measure for the AMPA receptor binding study was specific bound
radioactivity. Raw data is presented in Table 3. Data was first checked for normality using the
Lilliefors test, which revealed a normal distribution (D(20)=0.14, p=0.34). As a result, outliers
were detected through Pierce’s criterion, leaving a final sample of 19 animals. An F test revealed
that equal variances can be assumed (F(9,9)=2.86, p=0.13). An independent samples t-test was
conducted for average specific bound radioactivity between the two dose groups, revealing that
AMPA receptor expression differed as a function of dose (t(17)= -2.15, p < 0.05, η 2=0.21). Higher
AMPA expression was detected in the dorsal hippocampus of animals dosed with 10 mg/kg of
(2R,6R)-HNK compared to vehicle, confirming our primary hypothesis (Figure 4).
The Effect of (2R,6R)-HNK on Novel Object Placement Preference Scores. Raw data
for OP preference scores is presented in Table 4, while grouped OP preference score data is
presented in Figure 5. Each animal’s preference for the bottle in the novel location during the
retention trial of the OP task was quantified by two independent raters blind to the dose conditions.
Their calculated preferences scores resulted in an interrater reliability coefficient of 0.87, R2 =
0.75. Lilliefors test on residuals of the preference data revealed that the data was normally
distributed (D(60)=0.068, p=0.70). Since the data was normally distributed, Pierce’s criterion was
used to detect outliers. No outliers were detected and a one-way between-subjects ANOVA was
conducted on the sample of 60 animals. Levene’s test found that homogeneity of variance was not
violated (F(3,56)=0.077, n.s.). A one-way between subjects ANOVA found there was no
difference between groups in preference for the bottle in the novel location (F(3,56)=0.26, n.s.).
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Administration of 1 mg/kg, 3 mg/kg, or 10 mg/kg (2R,6R)-HNK did not result in cognitive
improvements in spatial memory compared to vehicle as assessed by the OP task. The ANOVA
resulted in an η2 of 0.014, which is considered a very small effect size.

A priori-defined Secondary Analyses:
The Effect of (2R,6R)-HNK on Total Exploration Time During the Retention Trial.
Total exploration times for both bottles in the retention trial of the OP task were explored as a
secondary dependent variable. Raw values are presented in Table 5. Lilliefors test of normality
was conducted on the residuals of the exploration time data, revealing that the scores were
normally distributed (D(60)=0.10, n.s.). This was followed by Pierce’s criterion test for the
detection of outliers. Two outliers were detected, leaving a final sample of 58 animals. Levene’s
test for homogeneity of variance found that the assumption of homogeneity of variance was not
violated (F(3, 54)=1.31, n.s.). A one-way between-subjects ANOVA revealed no effect of dose
condition on total exploration times (F(3, 54)=0.45, n.s.) with an effect size of 0.024. Exploration
time data is visualized in Figure 6.
The Effect of (2R,6R)-HNK on Distance Travelled During the Retention Trial. Total
distance travelled in centimeters in the retention trial of the OP task was also explored as a
secondary dependent variable, and is shown in Figure 7. Distance data is presented in Table 6.
Lilliefors test of normality was conducted on the residuals of the distance data from 60 animals,
revealing that the data was normally distributed (D(60)=0.075, p=0.56). Pierce’s criterion for
detecting outliers was implemented, resulting in the elimination of 3 outliers and a final sample of
57 animals. Levene’s test found that variance was homogeneous across groups (F(3, 54)= 1.27,
n.s.). A one-way between-subjects ANOVA was conducted and revealed no effect of dose
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condition on the total distance travelled during the RT phase (F(3, 53)=0.96, n.s., η 2=0.051),
suggesting that there were no differences in motor function across treatment groups.

Exploratory Analyses:
The Effect of (2R,6R)-HNK on AMPA Receptor Binding in the Cornu Ammonis Area
1 (CA1) Hippocampal Subregion. We conducted an exploratory analysis of specific bound
radioactivity in the CA1 regions of our hippocampal slices in order to investigate AMPA
expression in this region. Raw data for bound radioactivity in the CA1 is also presented in Table
3. The data was first checked for normality with the Lilliefors test and was confirmed to be
normally distributed (D(20)=0.17, n.s.). The same outlier that was detected in the primary AMPA
analysis was once again detected and eliminated from analysis. An F test revealed that equal
variances can be assumed (F(8,9)=2.06, n.s.). An independent samples t-test of specific bound
radioactivity in the CA1 region of the hippocampus revealed significantly higher bound
radioactivity in rats dosed with 10 mg/kg (2R,6R)-HNK compared to vehicle (t(17)= -2.61, p<0.05,
η 2=0.29). This suggests that AMPA expression is enhanced compared to vehicle 24 hours after
10mg/kg (2R,6R)-HNK administration in the CA1 region of the hippocampus. Data visualizations
are presented in Figure 4.

Discussion
We hypothesized that 24 hours after administration, a single injection of 10 mg/kg (2R,6R)HNK would result in increased AMPA expression compared to vehicle in the dorsal hippocampus
of rats. Analysis of the autoradiography data confirmed this hypothesis for the approximate
hippocampal region of 2.40 mm to 3.00 mm posterior from Bregma. As an exploratory analysis,
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we then narrowed the region of interest to the CA1 in the same slices, and once again found higher
AMPA expression in rats injected with (2R,6R)-HNK compared to vehicle with some evidence of
a modestly larger effect size. Additionally, we hypothesized that this increased AMPA expression
would result in improved cognitive function in the form of enhanced spatial memory in the
hippocampally-dependent OP task. Our data did not confirm this hypothesis, showing no
difference in spatial memory between normal rats injected with vehicle, 1 mg/kg, 3 mg/kg or 10
mg/kg (2R,6R)-HNK 24 hours prior to testing. There were also no differences between groups in
total exploration times or total distance travelled during the RT phase of the OP task. The results
of this study suggest that intraperitoneal administration of (2R,6R)-HNK does in fact enhance
AMPA expression in the hippocampus. However, the resulting increase in AMPA activity is not
sufficient enough to affect spatial memory function in normal rats.

The Link Between (2R,6R)-HNK and Glutamatergic Neurotransmission
Our autoradiography data shows that (2R,6R)-HNK leads to AMPA receptor upregulation,
which is in line with previous work. Zanos et al. (2016) demonstrated increases in AMPA receptormediated excitatory postsynaptic potentials (EPSPs) in the CA1 region of the hippocampus in mice
24 hours after (2R,6R)-HNK administration, as well as increases in the expression of AMPA
receptor subunits GluA1 and GluA2, assessed using Western blot. They also tested the relationship
between (2R,6R)-HNK administration and AMPA receptor activity in the mouse forced swim test
(FST), a putative model of depression. Administration of 10 mg/kg (2R,6R)-HNK 24 hr i.p.
reduced immobility time in the FST, a response putatively associated with antidepressant-like
actions. Acute treatment with NBQX, an AMPA receptor antagonist, did not result in similarly
reduced immobility time, implying that AMPA receptor activity is required in order for (2R,6R)-

THE EFFECTS OF (2R,6R)-HNK ON AMPA AND OP PERFORMANCE

40

HNK’s antidepressant-like effects. Preliminary work in human cells has also linked (2R,6R)-HNK
and AMPA receptor activity. Human induced pluripotent stem cells that were differentiated into
dopaminergic neurons in vitro were treated with (2R,6R)-HNK for 6 hours, and showed increased
dendritic outgrowth when measured 3 days after treatment, suggesting increased, long-lasting
synaptic plasticity as a result (Collo et al, 2018). A similar effect was seen after treatment with
ketamine. This study further tied both (2R,6R)-HNK and ketamine to AMPA receptor expression
in human cells after pretreatment with NBQX resulted in an impairment of dendritic outgrowth in
these neurons.
Ketamine and (2R,6R)-HNK are thought to invoke similar changes in neurotransmission
with the exception of ketamine’s NMDA antagonism. Both drugs result in increases AMPA
expression in the hippocampus 24 hours post-administration, and both drugs rely on continued
AMPA receptor activity in order to sustain their antidepressant action in behavioral depression
models like the FST and learned helplessness test (Pham et al, 2017; Tizabi et al, 2012; Graef et
al, 2015). There is conflicting evidence on whether the metabolism of ketamine into its S,R-HNK
metabolites is necessary for ketamine’s antidepressant effects. It has been shown that if the rate of
metabolism of ketamine into (2R,6R)-HNK is decelerated, it is no longer possible for ketamine to
sustain its behavioral antidepressant effects in the FST or the learned helplessness test at the 24hour timepoint (Zanos et al, 2016; Hashimoto, 2016). This discovery allowed Zanos and
colleagues to attribute ketamine’s beneficial behavioral effects directly to (2R,6R)-HNK.
However, in a direct response to this finding, Yamaguchi et al. (2018) found contrasting results
after completely ablating ketamine’s ability to metabolize into (2R,6R)-HNK. In the FST,
immobility time was significantly lower for the group injected with ketamine and metabolism
inhibitors compared to saline, while groups not injected with metabolism inhibitors did not differ
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from saline. This means that allowing ketamine to metabolize into (2R,6R)-HNK actually hindered
performance. A major difference between the two studies, however, is that Yamaguchi et al. (2018)
looked at the behavioral effects of the drugs only 3 hours after administration, while Zanos et al.
(2016) originally looked at the effects of the drugs after 24 hours. Considering that ketamine has
a half-life of 2-3 hours, the amount of drug left in the body during the 3-hour and 24-hour
timepoints will differ tremendously, making it difficult to compare the findings of both papers.
Though there is not yet a depth of knowledge on (2R,6R)-HNK’s mechanism of action in
terms of antidepressant cognitive effects, it is clear that it is linked to AMPA receptor activity
(Fukumoto et al, 2017). Our findings provide support for this idea. The rationale of our study was
partially based on findings from Graef et al. (2015) that suggested enhancement of LTP in the
hippocampus 24 hours after ketamine administration. As we have shown, (2R,6R)-HNK
administration enhances AMPA expression in the hippocampus, which should be related to
increased LTP (Tocco et al, 1992). While upregulating AMPA receptors, (2R,6R)-HNK also
manages to mostly avoid blocking NMDA receptors to exert its effects (Lumsden et al, 2019).
Simply blocking the activity of NMDA receptors with other antagonists such as MK-801 does not
result in the same antidepressant effect in tasks like the FST (Zanos et al, 2016). Therefore, it is
the augmenting interaction with AMPA receptors and not NMDA receptors that defines (2R,6R)HNK’s efficacy.

Evaluating the OP Task as a Valid Measure of Spatial Memory
The Novel Object Placement (OP) task is commonly used to assess changes in spatial
memory in rodents (Broadbent, Squire, & Clark, 2014; Barker & Warburton, 2011; Westbrook,
Brennan, & Stanton, 2014; Assini, Duzzioni, & Takahashi, 2009). Other common rodent models

THE EFFECTS OF (2R,6R)-HNK ON AMPA AND OP PERFORMANCE

42

of spatial memory performance include the 8-arm radial maze, T-maze, the Morris water maze,
and the Barnes maze. Unlike the OP task, these spatial memory tasks utilize negative or positive
reinforcement techniques in order to promote spatial learning (Savage & Ma, 2014). In the 8-arm
radial maze, a food reward is placed at the end of each arm on the platform, all of which are
equidistant from the center of the maze. The rat is placed in the center of the maze and its memory
for the spatial orientation of the maze is evaluated based on how often the animal re-enters an arm
(indicating memory deficits). Similarly, the T-maze consists of a platform in the shape of a “T”,
with a food reward alternating between the two arms of the maze. Spatial memory performance is
assessed based on how well the animal learns to alternate between arms when searching for the
reward. In both the Morris and Barnes mazes, a negative stimulus (cold water or a very brightlylit platform, respectively) is used to incentivize the animal to successfully navigate the spatial
maze. Unfortunately, these four spatial memory tasks may be confounded by the use of positive
and negative reinforcements, which can add an emotional component to the task (fear or anxiety
in the Morris and Barnes mazes, and excitement or anticipation in the arm mazes), and require
training that may influence results of pharmacological testing. The OP task is simple enough to
not evoke any external memories or emotional components that may interfere with measuring
spatial memory, making it a good measure of spatial memory.
The use of drugs with known nootropic (i.e. cognition and memory enhancing) properties
has been used to evaluate whether these spatial memory tasks are able to detect improvements in
spatial memory in both normal and stress-treated rats. Modafinil, a psychostimulant that boosts
glutamate and dopamine neurotransmission, is used to promote wakefulness, attentiveness, and
related cognition. In relation to the OP task, it has been shown to reverse spatial memory deficits
that result from chronic methamphetamine abuse in Long Evans rats (Reichel et al, 2014). Whereas
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meth-treated control rats did not differentiate between the objects during the RT phase, methtreated rats given modafinil spent more time exploring the object in the novel location, illustrating
a reversal of meth-induced spatial memory deficits. Similar improvements in memory have been
seen using modafinil in the Morris water maze and arm mazes after deficits caused by sleep
deprivation and other chronic stress models impaired spatial memory function (Shuman, Wood, &
Anagnostaras, 2009; Piérard et al, 2007; Piérard et al, 2006). Similarly, nicotine and donepezil,
known to enhance memory performance, have also been used in conjunction with the OP task,
demonstrating that this task is in fact capable of detecting memory improvements in normal
animals (Melichercik et al, 2012; Karamihalev, Prickaerts, & van Goethem, 2014). In normal rats,
nicotine, an acetylcholine receptor agonist, leads to short periods of stimulation that enhance
spatial memory in the OP task compared to saline, but which cause functional antagonism due to
receptor desensitization, leading to memory deficits after prolonged use (Kenney et al, 2011;
Melichercik et al, 2012). Nonetheless, the memory impairments in the OP task resulting from
chronic nicotine use speak more so to the mechanistic features of nicotine than to the validity of
the OP task. Finally, the acetylcholinesterase inhibitor donepezil also improves spatial memory
OP performance in mice treated with MK-801, the NMDAR antagonist (Karamihalev, Prickaerts,
& van Goethem, 2014). Chronic treatment with MK-801 led to lasting memory deficits due to
inhibition of glutamatergic activity at NMDARs, and this deficit was reversed after treatment with
donepezil. This collective evidence provides support for the use of the OP task in assessing spatial
memory changes with (2R,6R)-HNK.
Our primary behavioral hypothesis was that treatment with (2R,6R)-HNK 24 hours prior
to testing would result in enhanced spatial memory performance in the OP task. This hypothesis
was based on findings suggesting that the hippocampus is responsible for successful OP task

THE EFFECTS OF (2R,6R)-HNK ON AMPA AND OP PERFORMANCE

44

performance and that ketamine enhances LTP in the hippocampus, which should further aid in OP
performance (Barker & Warburton, 2011; Graef et al, 2015). Successful completion of the OP task
also depends on proper NMDA receptor function (Assini, Duzzioni, & Takahashi, 2009; Jablonski
et al, 2013). When treated with the NMDA receptor antagonist MK-801, rodents are impaired in
their OP spatial memory performance, while treatment with NMDA receptor agonist Dcycloserine enhances OP performance compared to vehicle (Assini, Duzzioni, & Takahashi, 2009).
Since (2R,6R)-HNK does not alter NMDA functioning, it would be expected to lead to more
accurate performance than ketamine in the OP task.
There is also evidence that it is the CA1 region of the hippocampus specifically that aids
in spatial memory performance in the OP task. When lidocaine is infused into the CA1 to disrupt
function, performance in the OP task is impaired (Assini, Duzzioni, & Takahashi, 2009). This
aligns with Barker & Warburton’s (2011) finding that a bilateral lesion of the hippocampus impairs
OP performance while lesions of the medial prefrontal cortex or perirhinal cortex do not. When
hippocampal lesions are only unilateral, performance is not impaired, presumably because the CA1
is still unilaterally intact. Still, the link between hippocampal AMPA expression, LTP, and
observable spatial memory performance may not be as strong as researchers in the field may
believe, as we were unable to demonstrate enhanced performance in the OP task despite increases
in hippocampal CA1 AMPA expression. These results may be explained by findings suggesting
that (2R,6R)-HNK does not have as robust of an antidepressant response as ketamine at the same
doses. Though we observed enhanced AMPAR activity at 10 mg/kg of (2R,6R)-HNK, it is possible
that behavioral enhancements in spatial memory require a higher dose. It must be noted that there
is a limited amount of work that uses the OP task in rodents in conjunction with (2R,6R)-HNK or
ketamine. Ketamine and its metabolites have been used to demonstrate performance enhancements
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in mood tasks such as the FST or learned helplessness test and cognitive tasks such as the attention
set-shifting test (AST). Of course, it also possible that LTP enhancements in response to (2R,6R)HNK may bolster some forms of cognition (e.g. attention) instead of others (e.g. memory).
However, this possibility needs to be thoroughly tested with both (2R,6R)-HNK and ketamine in
several cognitive tasks.

Limitations and Future Directions
This study may be the first to use (2R,6R)-HNK to study spatial memory performance in
the OP task and thus requires replication. Replication is also required of the influence of (2R,6R)HNK on AMPAR expression, specifically with an a priori-defined hypothesis of enhanced AMPA
expression in the hippocampal CA1 subregion as our analysis was only exploratory. Future
investigations into the influence of (2R,6R)-HNK on AMPA receptor expression must also
establish whether successful OP performance depends on AMPA activation the same way that it
depends on NMDA activation. This could be accomplished with a comparison of OP performance
after treatment with (2R,6R)-HNK + NBQX to block the activation of AMPA receptors. Though
(2R,6R)-HNK did not show significant improvements in spatial memory performance in this study,
the increased hippocampal AMPA receptor functioning that was observed still has implications
for the field. Firstly, (2R,6R)-HNK solves the issue of undesirable psychotomimetic side effects
caused by ketamine’s NMDA receptor antagonism. Secondly, the increases in AMPA expression
seen after (2R,6R)-HNK administration suggest that there is the potential for increased synaptic
plasticity 24 hours after administration. Though these findings are tenuous and in need of
replication, they are in line with the research literature.
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It is also possible that the link between hippocampal AMPA receptor expression, LTP, and
spatial memory performance may differ profoundly in chronically stressed rats due to a variety of
problems with glutamatergic neurotransmission. The current study was conducted in a sample of
normal rats, which may have played a role in our observation of no differences in spatial memory
between saline and (2R,6R)-HNK dose groups. The use of normal animals may produce a ceiling
effect of “optimal” spatial memory, making it difficult to detect enhancements in memory after
(2R,6R)-HNK administration. Although, it should be noted that there was plenty of room available
for these animals to improve performance to the theoretical maximum of OP performance (100%
preference for the novel placement), given that the average memory performance was only 63%.
Additionally, it can be seen as an advantage for (2R,6R)-HNK to not enhance spatial memory
compared to saline, given that several drugs are abused for their cognition-enhancing effects (e.g.
methylphenidate and d-amphetamine; Lakhan & Kirchgessner, 2012). Thus, the absence of
cognition-enhancing effects in normal subjects may reduce the abuse potential of this drug.
Therefore, it would be beneficial to examine the effects of (2R,6R)-HNK treatment in chronically
stressed male and female rats to determine whether enhancements in cognition can be detected in
a cognitively-impaired sample.
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Table 1. Affinity Table for NMDA receptor noncompetitive site inhibition. All values are
presented as pKi, with higher values indicating greater affinity for the noncompetitive NMDAR
binding site. As shown below, (2R,6R)-HNK has very low affinity for NMDA’s noncompetitive
receptor site. Affinity values were obtained by searching the National Institute of Mental Health's
Psychoactive Drug Screening Program database, Contract #HHSN-271-2018-00023-C (NIMH
PDSP; Roth et al, 2000), except where noted otherwise. *Affinity value for (2R,6R)-HNK was
obtained from Zanos et al, 2016, and is localized to the rat hippocampus.
Ligand
(2R,6R)-HNK
Memantine
Ketamine
PCP
MK-801

Receptor
Target
NMDA
NMDA
NMDA
NMDA
NMDA

pKi

Species

Location

Reference

< 5*
6.16
6.49
7.24
8.52

Rat
Rat
Rat
Rat
Rat

Hippocampus
Cortex
Forebrain
Forebrain
Forebrain

Zanos et al, 2016
Bresink et al, 1995
Wallach et al, 2016
Wallach et al, 2016
Wallach et al, 2016
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Table 2. This table displays the randomization of dose assignments for all animals. 20 animals
were used for AMPA binding analysis, were only assigned vehicle or 10mg/kg (2R,6R)-HNK, and
did not complete the OP task. 60 animals were assigned either 1, 3, 10 mg/kg (2R,6R)-HNK or
vehicle. 60 animals began the IT phase of the OP task 24 hours post-injection, and 20 animals were
sacrificed via decapitation 24 hours post-injection. CB represents randomized counterbalancing of
the object that moved to the novel location in the RT trial (either the “L” or “R” bottle).
Rat ID

Dose
(mg/kg)

Injection
(p.m.)

IT Start
(p.m.)

IT End
(p.m.)

RT Start
(p.m.)

RT End
(p.m.)

CB

R00043
R00044
R00045
R00046
R00047
R00048
R00049
R00050
R00051
R00052
R00053
R00054
R00055
R00056
R00057
R00058
R00059
R00060
R00061
R00062
R00063
R00064
R00065
R00066
R00067
R00068
R00069
R00070
R00071
R00072
R00073
R00074
R00075
R00076
R00077

0
10
0
10
0
10
0
0
10
0
10
0
0
10
0
10
10
0
10
10
3
1
10
1
1
0
10
0
10
0
3
3
1
3
1

1:30
1:40
1:50
2:00
2:10
2:20
2:30
2:40
2:50
3:00
3:10
3:20
3:30
3:40
3:50
4:00
4:10
4:20
4:30
4:40
1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02
4:24
4:31
4:53

----------------------------------------1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02
4:24
4:31
4:53

----------------------------------------1:35
1:42
2:04
2:11
2:33
2:40
3:02
3:09
3:31
3:38
4:00
4:07
4:29
4:36
4:58

----------------------------------------1:45
1:52
2:14
2:21
2:43
2:50
3:12
3:19
3:41
3:48
4:10
4:17
4:39
4:46
5:08

----------------------------------------1:50
1:57
2:19
2:26
2:48
2:55
3:17
3:24
3:46
3:53
4:15
4:22
4:44
4:51
5:13

----------------------------------------L
L
L
L
L
L
L
L
R
R
R
R
R
R
R
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R00078
R00079
R00080
R00081
R00082
R00083
R00084
R00085
R00086
R00087
R00088
R00089
R00090
R00091
R00092
R00093
R00094
R00095
R00096
R00097
R00098
R00099
R00100
R00101
R00102
R00103
R00104
R00105
R00106
R00107
R00108
R00109
R00110
R00111
R00112
R00113
R00114
R00115
R00116
R00117
R00118
R00119
R00120
R00121
R00122

0
3
10
0
0
10
0
1
0
1
10
10
10
3
0
1
1
10
0
3
3
0
10
10
0
1
1
1
10
0
1
3
10
3
1
3
10
3
0
3
1
0
10
3
3

5:00
1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02
4:24
4:31
4:53
5:00
1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02
4:24
4:31
4:53
5:00
1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02

5:00
1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02
4:24
4:31
4:53
5:00
1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02
4:24
4:31
4:53
5:00
1:30
1:37
1:59
2:06
2:28
2:35
2:57
3:04
3:26
3:33
3:55
4:02

5:05
1:35
1:42
2:04
2:11
2:33
2:40
3:02
3:09
3:31
3:38
4:00
4:07
4:29
4:36
4:58
5:05
1:35
1:42
2:04
2:11
2:33
2:40
3:02
3:09
3:31
3:38
4:00
4:07
4:29
4:36
4:58
5:05
1:35
1:42
2:04
2:11
2:33
2:40
3:02
3:09
3:31
3:38
4:00
4:07

5:15
1:45
1:52
2:14
2:21
2:43
2:50
3:12
3:19
3:41
3:48
4:10
4:17
4:39
4:46
5:08
5:15
1:45
1:52
2:14
2:21
2:43
2:50
3:12
3:19
3:41
3:48
4:10
4:17
4:39
4:46
5:08
5:15
1:45
1:52
2:14
2:21
2:43
2:50
3:12
3:19
3:41
3:48
4:10
4:17
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5:20
1:50
1:57
2:19
2:26
2:48
2:55
3:17
3:24
3:46
3:53
4:15
4:22
4:44
4:51
5:13
5:20
1:50
1:57
2:19
2:26
2:48
2:55
3:17
3:24
3:46
3:53
4:15
4:22
4:44
4:51
5:13
5:20
1:50
1:57
2:19
2:26
2:48
2:55
3:17
3:24
3:46
3:53
4:15
4:22

R
R
R
R
R
R
R
R
R
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
R
R
R
R
R
R
R
R
R
R
R
R
R
R
L
L
L
L
L
L

THE EFFECTS OF (2R,6R)-HNK ON AMPA AND OP PERFORMANCE

66

Table 3. Shown below are specific bound radioactivity values for dorsal hippocampal AMPA
receptors in the approximate region of -2.40mm to -3.00mm from Bregma of 20 Long Evans rats
as well as the CA1 region in the same brains. The CA1 binding analysis was exploratory. Specific
bound percentage values are calculated out of total bound radioactivity ([specific
bound]/[nonspecific bound + specific bound] x 100). NSB=nonspecific bound.

Rat ID

Dose

NSB

Specific
Bound

% Specific
Bound

NSB
(CA1)

R00043
R00044
R00045
R00046
R00047
R00048
R00049
R00050
R00051
R00052
R00053
R00054
R00055
R00056
R00057
R00058
R00059
R00060
R00061
R00062

0
10
0
10
0
10
0
0
10
0
10
0
0
10
0
10
10
0
10
10

14.8875
20.365
16.72
19.5725
16.705
16.5675
14.625
15.015
17.1725
14.3175
15.2025
15.045
13.0825
14.995
14.8425
11.8425
12.84
18.8575
16.3925
17.19

47.9875
44.8475
36.32
41.96
38.2725
49.885
44.31
52.25
56.0875
42.3
41.3225
58.0525
42.9775
44.15
35.82
47.1825
46.16
36.44
46.4575
50.52

76.32206759
68.77132452
68.47662142
68.19160606
69.61484244
75.06865806
75.18452532
77.67784137
76.55951406
74.71188237
73.10482088
79.41790075
76.66339636
74.64705385
70.70318283
79.9364676
78.23728814
65.89809666
73.91805887
74.61231724

16.73
17.7025
16.38
20.0375
17.2525
18.545
15.9975
14.3325
18.4775
14.31
15.85
15.7375
13.4725
15.96
14.2725
12.155
12.245
18.525
16.005
17.8175

Specific
Bound
(CA1)
52.745
48.385
36.4575
45.65
38.6025
50.8875
42.64
57.43
61.5675
45.285
46.83
70.8175
46.5025
48.9275
36.3425
49.34
54.755
43.085
53.2825
57.185

%Specific
Bound
(CA1)
75.91939547
73.21354265
68.99929028
69.49571836
69.11198639
73.29060598
72.71797058
80.02786971
76.91610969
75.98791845
74.71282706
81.81791924
77.53647353
75.40358312
71.8018374
80.23416538
81.7238806
69.93182925
76.90059535
76.2441252
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Table 4. Preference scores are presented as percentages of the time spent exploring the object in
the novel location out of the total amount of time spent exploring both objects during the retention
trial. The scores resulted in an inter-rater reliability coefficient of 0.87, R2 = 0.75.
Rat ID
R00063
R00064
R00065
R00066
R00067
R00068
R00069
R00070
R00071
R00072
R00073
R00074
R00075
R00076
R00077
R00078
R00079
R00080
R00081
R00082
R00083
R00084
R00085
R00086
R00087
R00088
R00089
R00090
R00091
R00092

OP Preference
Score Coder 1
81.21783877
62.72727273
79.75632615
55.54973822
57.30718461
70.89682738
71.83916183
76.37267081
96.90189329
35.07793273
71.75007403
69.30518909
87.69230769
85.81173261
32.57810637
57.68772348
49.17424605
57.59874759
71.78334404
75.22123894
56.82210708
48.44649022
59.50576606
69.41056911
56.12695862
59.49704706
58.45896147
67.6331049
78.65125241
64.81570129

OP Preference
Score Coder 2
74.62555066
56.13114754
73.08367466
51.52656355
56.43971631
68.04397271
66.65539779
77.22938867
92.68592502
32.13420079
60.15037594
60.76850984
82.41042345
75.04432624
33.92608628
29.93421053
49.4362453
55.82969432
74.79725515
79.85905045
54.93634398
40.21862578
59.65703971
67.36518581
64.61009174
55.58026407
54.11977492
66.43102404
72.94472362
64.81196393

Rat ID
R00093
R00094
R00095
R00096
R00097
R00098
R00099
R00100
R00101
R00102
R00103
R00104
R00105
R00106
R00107
R00108
R00109
R00110
R00111
R00112
R00113
R00114
R00115
R00116
R00117
R00118
R00119
R00120
R00121
R00122

OP Preference OP Preference
Score Coder 1 Score Coder 2
88.60759494
91.52054436
60.13986014
61.17160279
62.67848351
64.35170436
70.17808633
73.32759733
72.83451298
75.04509922
45.23305085
55.05339436
82.33618234
84.62956137
48.40909091
31.75675676
48.8909427
65.85945625
47.31591449
45.35204209
37.82998944
29.07332599
73.40019102
70.05509642
72.64653641
63.29713722
62.74859009
45.53699284
48.67517174
52.46345425
51.80144115
60.05173688
55.4619226
57.40479549
39.09952607
23.58591249
56.67485667
37.51672862
74.95327103
72.26640159
70.55865922
69.29793922
75.20404197
75.2372093
62.27955585
58.92799483
60.38095238
68.69386708
89.82035928
86.7485182
61.28318584
58.83865438
76.83435583
79.94505495
64.4012945
64.26389737
49.61127308
61.08855811
60.69972826
75.83396995

THE EFFECTS OF (2R,6R)-HNK ON AMPA AND OP PERFORMANCE

68

Table 5. Shown below are total exploration times of both bottles (in seconds) during the retention
trial of the OP task.

Rat ID
R00063
R00064
R00065
R00066
R00067
R00068
R00069
R00070
R00071
R00072
R00073
R00074
R00075
R00076
R00077
R00078
R00079
R00080
R00081
R00082
R00083
R00084
R00085
R00086
R00087
R00088
R00089
R00090
R00091
R00092

Total Explo. Total Explo.
Coder 1 (s)
Coder 2
11.66
11.35
12.1
15.25
10.67
17.09
57.3
74.35
53.03
70.5
40.03
52.76
70.63
88.74
20.125
35.66
11.62
16.27
60.95
78.39
33.77
53.2
34.11
53.35
33.8
46.05
14.66
22.56
41.93
64.67
16.78
39.52
83.56
109.09
83.04
91.6
46.71
64.12
16.95
26.96
34.74
41.63
52.14
70.44
30.35
44.32
29.52
35.79
24.89
43.6
52.49
71.95
29.85
49.76
37.94
49.51
25.95
49.75
20.89
45.47

Rat ID
R00093
R00094
R00095
R00096
R00097
R00098
R00099
R00100
R00101
R00102
R00103
R00104
R00105
R00106
R00107
R00108
R00109
R00110
R00111
R00112
R00113
R00114
R00115
R00116
R00117
R00118
R00119
R00120
R00121
R00122

Total Explo. Total Explo.
Coder 1 (s) Coder 2 (s)
18.96
38.21
15.73
45.92
40.62
62.78
66.26
92.98
29.67
66.52
28.32
52.44
10.53
27.13
17.6
54.76
21.64
67.31
21.05
39.91
37.88
81.69
20.94
36.3
45.04
50.65
33.69
62.85
20.38
36.94
12.49
27.06
32.04
49.63
8.44
28.11
24.42
67.25
42.8
60.36
17.9
28.63
25.73
53.75
30.62
61.94
15.75
38.97
10.02
23.62
22.6
46.67
40.75
69.16
24.72
65.48
41.16
66.51
29.44
78.54
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Table 6. Shown below is the total distance travelled (in centimeters) during the retention trial of
the OP task. The scores were obtained via SMART video-tracking software (Harvard Apparatus,
Holliston, MA).
Rat ID Distance Travelled (cm)
R00063
2899.15
R00064
2529.46
R00065
1916.23
R00066
4015.37
R00067
2950.73
R00068
3139.17
R00069
2706.52
R00070
2338.1
R00071
2073.14
R00072
1896.7
R00073
2485.68
R00074
2494.57
R00075
2648.56
R00076
2552.17
R00077
2879.35
R00078
2061.37
R00079
3268.78
R00080
3235.74
R00081
2669.71
R00082
5590.22
R00083
2493.04
R00084
2430.9
R00085
2827.42
R00086
2010.68
R00087
2853.18
R00088
3449.85
R00089
3588.16
R00090
2276.09
R00091
2492.38
R00092
2810.42

Rat ID Distance Travelled (cm)
R00093
3023.91
R00094
3088.72
R00095
4517.52
R00096
3533.79
R00097
2810.88
R00098
3352.86
R00099
1072.09
R00100
3153.1
R00101
2055.58
R00102
3069.62
R00103
3797.6
R00104
2942.42
R00105
3533.59
R00106
2223.91
R00107
3576.56
R00108
2402.02
R00109
3027.22
R00110
1805.67
R00111
4351.69
R00112
2525.6
R00113
1547.59
R00114
3393.3
R00115
2759.16
R00116
3036.62
R00117
3019.64
R00118
3154.13
R00119
3216.18
R00120
3090.95
R00121
2850.86
R00122
2968.16
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Figure 1. These plastic white bottles with narrow necks were used in the novel object placement
task. The pair on the left were used during the IT trials, and the pair on the right were used during
the RT trials to prevent rats from scent-marking the bottles between trials. They are all identical.
The bottles are 2.69 inches in base diameter and 7 inches in height.
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Figure 2. The image on the left shows the layout of the objects during the IT phase for all animals.
In the middle and on the right are the layouts of the objects during the RT phase. The identity of
the object in the novel location (either the left or the right) was counterbalanced across all groups.
Each rat received only one RT trial with either the left or the right bottle in the novel location.
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Figure 3. Timeline of procedures. The AMPA group (N=20) was euthanized exactly 24 hours post-injection. The behavioral group
(N=60) began the OP task exactly 24 hours post-injection.
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Figure 4. Effects of (2R,6R)-HNK administration (24 hr i.p.) on AMPA receptor binding in
adult male rats. A. Treatment with (2R,6R)-HNK resulted in increased AMPA binding at
10mg/kg. Data are represented as Mean ± SEM. B. AMPA binding across groups had relatively
small levels of variation. Dots represent average group binding values, while violin plots represent
individual variation around the mean. C. Treatment with (2R,6R)-HNK resulted in increased
AMPA binding at 10mg/kg in the CA1 hippocampal subregion. Data are represented as Mean ±
SEM. D. AMPA binding in the CA1 had small levels of variation. E. Autoradiographic image of
specific-bound AMPA expression, showing noticeable binding in the CA1. F. Autoradiographic
image of nonspecific-bound AMPA expression.
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Figure 5. Effects of (2R,6R)-HNK administration (24 hr i.p.) on novel object placement
preference scores in adult male rats. A. Treatment with (2R,6R)-HNK did not alter novel object
placement preference scores at any dose. Data are represented as Mean ± SEM. B. Preference
scores had relatively small levels of variation. Dots represent average group novel object
placement preference scores, while violin plots represent individual variation around the mean.
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Figure 6. Effects of (2R,6R)-HNK administration (24 hr i.p.) on total exploration times
during the RT phase of the OP task in adult male rats. A. Treatment with (2R,6R)-HNK did
not affect total exploration times at any dose. Data are represented as Mean ± SEM. B. Exploration
times had relatively small levels of variation. Dots represent average total group exploration times,
while violin plots represent individual variation around the mean.
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Figure 7. Effects of (2R,6R)-HNK administration (24 hr i.p.) on total distance travelled
during the RT phase of the OP task in adult male rats. A. Treatment with (2R,6R)-HNK did
not affect total distance travelled at any dose. Data are represented as Mean ± SEM. B. Distance
travelled had relatively small levels of variation. Dots represent average total distance travelled,
while violin plots represent individual variation around the mean.
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CONFIDENTIAL -FOR PEER-REVIEW ONLY
Effects of (2R,6R)-HNK on AMPA Expression and OP Task Performance (#34969)
Created: 02/03/2020 02:47 PM (PT)
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This pre-registration is not yet public. This anonymized copy (without author names) was created by the author(s) to use during peer-review.
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this pre-registration are confidential.
1) Have any data been collected for this study already?
No, no data have been collected for this study yet.
2) What's the main question being asked or hypothesis being tested in this study?
The effects of (2R,6R)-hydroxynorketamine (HNK), a metabolite of ketamine, will be investigated on a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) expression and performance in the Novel Object Placement (OP) task. Ketamine has been shown to have antidepressant-like effects on cognitive
function 24 hours post-administration, including enhanced long-term potentiation (LTP) in the hippocampus. Enhanced LTP is linked to increased AMPA
expression and is an indication of synaptic plasticity, which aids in healthy cognitive function. Administration of (2R,6R)-HNK appears to have identical
effects without the adverse dissociative effects characteristic of ketamine. Therefore, there should be an increase in AMPA receptor binding 24 hours
post-administration of 10 mg/kg (2R,6R)-HNK relative to the vehicle group because of increases in LTP. There should also be an enhancement of cognitive
function in the form of improved spatial memory in the OP task 24 hours after injection of 10mg/kg (2R,6R)-HNK relative to vehicle due to increased
synaptic plasticity. The AMPA binding experiment will be conducted twice: first in a behaviorally-naïve group of rats and again immediately upon
completion of the OP task in the behavioral group in an effort to replicate and strengthen the AMPA experiment data.
3) Describe the key dependent variable(s) specifying how they will be measured.
The primary dependent variable in the behavioral experiment will be each rat's preference for the object in the novel location during the retention trial of
the OP task. Preference will be calculated as follows: (amount of time spent exploring the object in the novel location)/(total amount of time spent
exploring both objects) x 100. Exploration of an object is defined as facing the object with < 2 cm distance, and interacting with or sniffing the object. For
the autoradiography experiments, optical intensity values will be quantified from dorsal hippocampus slices using ImageQuant TL software (GE Healthcare,
Pittsburgh, PA). The primary dependent measure for AMPA receptor binding is bound radioactivity, measured in units of fmol/mg of tissue. A standard
curve will be generated by linear regression of intensity measurements from tritium standards included in the slide cassette during exposure (American
Radiolabeled Chemicals, St. Louis, MO). Bound radioactivity values for tissue will be interpolated from optical intensity values by interpolating from the
standard curve (method described previously; Pehrson et al, 2018).
4) How many and which conditions will participants be assigned to?
The behavioral experiment will involve 4 dose groups: vehicle, 1 mg/kg, 3 mg/kg, or 10 mg/kg of (2R,6R)-HNK.
The autoradiography experiment will involve 2 dose groups: vehicle or 10 mg/kg of (2R,6R)-HNK.
5) Specify exactly which analyses you will conduct to examine the main question/hypothesis.
In cases where data is normally distributed, a one-way between-subjects ANOVA will be conducted, followed where appropriate by Tukey-Kramer tests. For
data that is non-normally distributed, the Kruskal Wallis nonparametric ANOVA will be used followed where appropriate by Mann-Whitney U tests.
6) Describe exactly how outliers will be defined and handled, and your precise rule(s) for excluding observations.
If data is normally distributed, outliers will be identified according to Peirce's criterion. If data is not normally distributed, outliers will not be removed.
7) How many observations will be collected or what will determine sample size? No need to justify decision, but be precise about exactly how the
number will be determined.
Autoradiography data will be collected from 20 Long Evans rats, split into 2 groups of 10. Behavioral data will be collected from 60 Long Evans rats, split
into 4 groups of 15. These same 60 rats will undergo an identical autoradiography procedure upon completing behavioral testing in an effort to replicate
and strengthen the autoradiography group's data. A total of 80 rats will be used.
8) Anything else you would like to pre-register? (e.g., secondary analyses, variables collected for exploratory purposes, unusual analyses planned?)
Two secondary dependent measures will be explored during the behavioral experiment: total exploration times and distance travelled during the
information and retention trials. Exploration times will be collected by independent researchers in order to establish interrater reliability scores. Distance
travelled and other locomotor activity will be collected via SMART video-tracking software (Harvard Apparatus, Holliston, MA).
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APPENDIX B
R Code for Behavioral Data Analysis
#Libraries
library(Rmisc)
library(tidyverse)
library(nortest)
library(rstatix)
library(ez)
library(psychReport)
library(viridis)
library(viridisLite)
library(shadowtext)
library(patchwork)
#Read HNK behavioral data into R. Set doses from numeric to factors.
HNK_Behavior_Data <- read_csv(file.choose())
HNK_Behavior_Data$Dose <- factor(HNK_Behavior_Data$Dose, levels=c('0','1','3','10'))
#Descriptive stats for preference data
HNKDescriptive <- summarySE(HNK_Behavior_Data, measurevar='NOP.Pref.Score.Coder1',
groupvars = 'Dose')
#Calculate residuals for preference data
Pref_residuals <- HNK_Behavior_Data %>% group_by(Dose) %>% mutate(Group_mean =
mean(NOP.Pref.Score.Coder1)) %>%
ungroup() %>% mutate(Residuals = NOP.Pref.Score.Coder1 - Group_mean) %>%
select(Rat.ID,Dose, NOP.Pref.Score.Coder1, Residuals) %>% arrange(Dose)
sum(Pref_residuals$Residuals)
#Sum: -2.131628e-14
#Check residuals for normality using the Lilliefors test.
lillie.test(Pref_residuals$Residuals)
#D= 0.068247, p= 0.6961, preference data is normally distributed.
#Since data is normal, check for outliers using Pierce's criterion.
OutlierPierce <- function(RawData){
Doubtful = 1
LastOutlier = 0
require(R.matlab)
PierceMat<-readMat('Pierce.mat')
R.table<-PierceMat[[1]]
CleanData<-RawData[!is.na(RawData)]
DataLength<-length(CleanData)
Average<- mean(CleanData)
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StDev<- sd(CleanData,na.rm = FALSE)
while(Doubtful>=1){
rval<-R.table[(DataLength-2),Doubtful]
MaxDev<-StDev*rval
Deviation<-abs(CleanData-Average)
LogicTest<-(Deviation>=MaxDev)
LogArray<-cbind(LogicTest)
OutlierSum<-sum(LogicTest)
OutlierDiff<-OutlierSum-LastOutlier
LastOutlier<-OutlierSum
if(OutlierDiff>=1){
Doubtful<-Doubtful+1
}else{
print(LogArray[,ncol(LogArray)])
print(which(LogArray == TRUE))
Doubtful=0
return(LogArray[,ncol(LogArray)])
}
}
}
Out_analysis <- OutlierPierce(Pref_residuals$Residuals)
Pref_residuals <- cbind(Pref_residuals, Out_analysis)
#No outliers in the preference score data.
#Analyze preference data using a one-way between-subjects ANOVA, with Tukey-Kramer posthoc tests were appropriate.
#All data is presented as mean and standard error of the mean (SEM), alpha is set at 0.05.
#ezANOVA checks for homogeneity of variance using Levene's test of for homogeneity of
variance.
Pref_ANOVA <- ezANOVA(HNK_Behavior_Data, dv= NOP.Pref.Score.Coder1, wid = Rat.ID,
between = Dose, detailed=T, return_aov = T)
print(Pref_ANOVA)
#F(3,56)=0.2625046, p=0.85, eta^2=0.0139 very small effect size.
#Levene's test of homogeneity of variance: F(3,56)= 0.07681, p= 0.9723. Variances are equal.
#Data does not differ between groups. Post hoc test not needed.
#-----------TOTAL EXPLORATION TIME ANALYSIS----------#Calculate residuals for total exploration times data
Explo_residuals <- HNK_Behavior_Data %>% group_by(Dose) %>% mutate(Group_mean =
mean(Total.Explo.RT.Coder1)) %>%
ungroup() %>% mutate(Residuals = Total.Explo.RT.Coder1 - Group_mean) %>%
select(Rat.ID,Dose, Total.Explo.RT.Coder1, Residuals) %>% arrange(Dose)
sum(Explo_residuals$Residuals) #6.394885e-14
#Sum: 6.394885e-14
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#Check exploration residuals for normality.
lillie.test(Explo_residuals$Residuals)
#D= 0.10127, p= 0.1314, exploration data is normally distributed.
Out_analysis <- OutlierPierce(Explo_residuals$Residuals)
Explo_residuals <- cbind(Explo_residuals, Out_analysis)
Explo_residuals_outliers <- Explo_residuals %>%
filter(Out_analysis == 'TRUE')
#2 outliers, R00079, R00080
#Remove outliers from the data set.
HNK_Behavior_Data_exploout <- HNK_Behavior_Data %>% filter(Rat.ID != 'R00079') %>%
filter(Rat.ID != 'R00080')
ExploDescriptive
<summarySE(HNK_Behavior_Data_exploout,
measurevar='Total.Explo.RT.Coder1', groupvars = 'Dose')
#Analyze exploration data using a one-way between-subjects ANOVA, with Tukey-Kramer posthoc tests were appropriate.
#All data is presented as mean and standard error of the mean (SEM), alpha is set at 0.05.
#ezANOVA checks for homogeneity of variance using Levene's test.
Explo_ANOVA <- ezANOVA(HNK_Behavior_Data_exploout, dv= Total.Explo.RT.Coder1, wid
= Rat.ID,
between = Dose, detailed=T, return_aov = T)
print(Explo_ANOVA)
#F(3,54)= 0.446, p= 0.7209, eta^2= 0.02419, very small effect size.
#Levene's test: F(3,54)= 1.305083, p= 0.2822. Variances are equal.
#Data does not differ between groups. Post hoc test not needed.
#-----------DISTANCE TRAVELLED ANALYSIS----------#Calculate residuals for distance travelled data
Dist_residuals <- HNK_Behavior_Data %>% group_by(Dose) %>% mutate(Group_mean =
mean(Total.Distance.RT)) %>%
ungroup() %>% mutate(Residuals = Total.Distance.RT - Group_mean) %>%
select(Rat.ID,Dose, Total.Distance.RT, Residuals) %>% arrange(Dose)
sum(Dist_residuals$Residuals) #1.818989e-12
#Sum: 1.818989e-12
#Check distance residuals for normality.
lillie.test(Dist_residuals$Residuals)
#D= 0.074604, p= 0.5575, distance data is normally distributed.
#Check distance data for outliers.
Out_analysis <- OutlierPierce(Dist_residuals$Residuals)
Dist_residuials <- cbind(Dist_residuals, Out_analysis)
Dist_residuals_outliers <- Dist_residuals %>% filter(Out_analysis == 'TRUE')
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#3 outliers, R82, R99, R95
#Remove outliers from the data set.
HNK_Behavior_Data_distout <- HNK_Behavior_Data %>% filter(Rat.ID != 'R00082') %>%
filter(Rat.ID != 'R00099') %>% filter(Rat.ID != 'R00095')
DistDescriptive <- summarySE(HNK_Behavior_Data_distout, measurevar='Total.Distance.RT',
groupvars = 'Dose')
#Analyze distance data using a one-way between-subjects ANOVA, with Tukey-Kramer post-hoc
tests were appropriate.
#All data is presented as mean and standard error of the mean (SEM), alpha is set at 0.05.
#ezANOVA checks for homogeneity of variance using Levene's test.
Dist_ANOVA <- ezANOVA(HNK_Behavior_Data_distout, dv= Total.Distance.RT, wid =
Rat.ID,
between = Dose, detailed=T, return_aov = T)
print(Dist_ANOVA)
#F(3,53)= 0.95529, p= 0.4207, eta^2= 0.0513, very small effect size.
#Levene's test: F(3,53)= 1.2706, p= 0.2939. Variances are equal.
#Data does not differ between groups. Post hoc test not needed.
#-----------BAR AND VIOLIN PLOTS FOR ALL DEPENDENT VARIABLES----------Quick_bar <- function(df, Ind_var, Dep_var, x_title, y_title, n_pos = 1, y_lim = c(0,NA)) {
# Dependencies
library(tidyverse)
library(viridis)
library(viridisLite)
library(shadowtext)
# Derives mean, standard error, and group sample size
descriptives <- df %>% group_by(!!sym(Ind_var)) %>%
summarize(n = n(), mean = mean(.data[[Dep_var]]),sd = sd(.data[[Dep_var]]),se = sd/sqrt(n))
# Plots a bar graph based on the called data frame
plot <- ggplot(descriptives, aes(x = as.factor(!!sym(Ind_var)) , y = mean, fill =
as.factor(!!sym(Ind_var)))) +
geom_bar(stat = 'identity', position = position_dodge(), color = 'black', size = 1.5) +
geom_errorbar(aes(ymin = mean - se, ymax = mean + se, width = 0.25), size = 1.1) +
theme_classic() +
scale_fill_viridis_d(begin = 0, end = 0.95, option = 'plasma', aesthetics = 'fill') +
geom_shadowtext(y = n_pos,label = sprintf('N=%s', paste0(descriptives$n)), size = 6, fontface
= 'bold') +
theme_classic() + labs(x = x_title, y = y_title) + theme(legend.position = 'none') +
theme(axis.text = element_text(size = 16, face = 'bold'),
axis.title = element_text(size = 20, face = 'bold'),
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plot.title = element_text(hjust = 0.5, size = 20, face = "bold"),
legend.title = element_text(size = 14, face = "bold"),
legend.text = element_text(size = 12, face = 'bold')) + ylim(y_lim)
return(plot)
}
Quick_violin <- function(df, Ind_var, Dep_var, x_title, y_title, y_lim = c(0,NA)) {
# Dependencies
library(tidyverse)
library(viridis)
library(viridisLite)
library(shadowtext)
# Derives mean, standard error, and group sample size
descriptives <- df %>% group_by(!!sym(Ind_var)) %>%
summarize(n = n(), mean = mean(.data[[Dep_var]]),sd = sd(.data[[Dep_var]]),se = sd/sqrt(n))
# Plots a violin plot based on the called data frame
plot <- ggplot(df, aes(x = as.factor(!!sym(Ind_var)) , y = .data[[Dep_var]], fill =
as.factor(!!sym(Ind_var)))) +
geom_violin(color = 'black', size = 1.5) +
scale_fill_viridis_d(begin = 0, end = 0.95, option = 'plasma', aesthetics = 'fill') +
theme_classic() + labs(x = x_title, y = y_title) + theme(legend.position = 'none') +
geom_pointrange(data = descriptives, aes(y = mean, ymin = mean-se, ymax = mean+se), size =
1.1) +
ylim(y_lim) +
theme(axis.text = element_text(size = 16, face = 'bold'),
axis.title = element_text(size = 20, face = 'bold'),
plot.title = element_text(hjust = 0.5, size = 20, face = "bold"),
legend.title = element_text(size = 14, face = "bold"),
legend.text = element_text(size = 12, face = 'bold'))
return(plot)
}
Pref_A <- Quick_bar(HNK_Behavior_Data, 'Dose','NOP.Pref.Score.Coder1','(2R,6R)HNK Dose
\n(mg/kg, 24 hr i.p.)',
'Preference Score (%)', 5, c(0,100)) + labs(title = '5A') +
theme(plot.title = element_text(hjust = 0))
Pref_B <- Quick_violin(HNK_Behavior_Data, 'Dose','NOP.Pref.Score.Coder1','(2R,6R)HNK
Dose \n(mg/kg, 24 hr i.p.)',
'Preference Score (%)', c(0,100)) + labs(title = '5B') +
theme(plot.title = element_text(hjust = 0))
Pref_A

THE EFFECTS OF (2R,6R)-HNK ON AMPA AND OP PERFORMANCE

83

Pref_B
Explo_A
<Quick_bar(HNK_Behavior_Data_exploout,
'Dose','Total.Explo.RT.Coder1','(2R,6R)HNK Dose \n(mg/kg, 24 hr i.p.)',
'Total Exploration Time (s)', 5, c(0,100)) + labs(title = '6A') +
theme(plot.title = element_text(hjust = 0))
Explo_B
<Quick_violin(HNK_Behavior_Data_exploout,
'Dose','Total.Explo.RT.Coder1','(2R,6R)HNK Dose \n(mg/kg, 24 hr i.p.)',
'Total Exploration Time (s)', c(0,100)) + labs(title = '6B') +
theme(plot.title = element_text(hjust = 0))
Explo_A
Explo_B
Dist_A <- Quick_bar(HNK_Behavior_Data_distout, 'Dose','Total.Distance.RT','(2R,6R)HNK
Dose \n(mg/kg, 24 hr i.p.)',
'Distance Travelled (cm)', 5, c(0,4000)) + labs(title = '7A') +
theme(plot.title = element_text(hjust = 0))
Dist_B <- Quick_violin(HNK_Behavior_Data_distout, 'Dose','Total.Distance.RT','(2R,6R)HNK
Dose \n(mg/kg, 24 hr i.p.)',
'Distance Travelled (cm)', c(0,4000)) + labs(title = '7B') +
theme(plot.title = element_text(hjust = 0))
Dist_A
Dist_B
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R Code for AMPA Binding Analysis
#Libraries
library(Rmisc)
library(tidyverse)
library(nortest)
library(rstatix)
library(ez)
library(psychReport)
library(viridis)
library(viridisLite)
library(patchwork)
#Read HNK AMPA data into R. Set doses from numeric to factors.
HNK_AMPA_Data <- read_csv(file.choose())
HNK_AMPA_Data$Dose <- factor(HNK_AMPA_Data$Dose, levels=c('0','10'))
#Descriptive stats for binding data
AMPADescriptive <- summarySE(HNK_AMPA_Data, measurevar='SB', groupvars = 'Dose')
AMPAOut_Descriptive <- summarySE(HNK_AMPA_Data_out, measurevar = 'SB', groupvars =
'Dose')
CA1Out_Descriptive <- summarySE(HNK_AMPA_Data_out, measurevar = 'SB_CA1',
groupvars = 'Dose')

#Calculate residuals for binding data
AMPA_residuals <- HNK_AMPA_Data %>% group_by(Dose) %>% mutate(Group_mean =
mean(SB)) %>%
ungroup() %>% mutate(Residuals = SB - Group_mean) %>%
select(Rat.ID,Dose, SB, Residuals) %>% arrange(Dose)
sum(AMPA_residuals$Residuals)
#Checksum = -7.1e-15, please check that you're getting the same value
#I get sum: -1.421085e-14
#Check residuals for normality using the Lilliefors test.
lillie.test(AMPA_residuals$Residuals)
#D= 0.14408, p= 0.3395, AMPA data is normally distributed.
#Since data is normal, check for outliers using Pierce's criterion.
OutlierPierce <- function(RawData){
Doubtful = 1
LastOutlier = 0
require(R.matlab)
PierceMat<-readMat('Pierce.mat')
R.table<-PierceMat[[1]]
CleanData<-RawData[!is.na(RawData)]
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DataLength<-length(CleanData)
Average<- mean(CleanData)
StDev<- sd(CleanData,na.rm = FALSE)
while(Doubtful>=1){
rval<-R.table[(DataLength-2),Doubtful]
MaxDev<-StDev*rval
Deviation<-abs(CleanData-Average)
LogicTest<-(Deviation>=MaxDev)
LogArray<-cbind(LogicTest)
OutlierSum<-sum(LogicTest)
OutlierDiff<-OutlierSum-LastOutlier
LastOutlier<-OutlierSum
if(OutlierDiff>=1){
Doubtful<-Doubtful+1
}else{
print(LogArray[,ncol(LogArray)])
print(which(LogArray == TRUE))
Doubtful=0
}
}
}
Out_analysis <- OutlierPierce(AMPA_residuals$Residuals) #R54
AMPA_residuals <- cbind(AMPA_residuals,Out_analysis)
AMPA_outlier <- CA1_residuals %>% filter(Out_analysis == 'TRUE')
#Remove outliers from the data set.
HNK_AMPA_Data_out <- HNK_AMPA_Data %>% filter(Rat.ID != 'R00054')
#Analyze AMPA binding data using an independent samples t-test.
var.test(HNK_AMPA_Data$SB ~ HNK_AMPA_Data$Dose)
#F(9,9) = 2.8567, p = 0.133. Variances are equal.
t.test(HNK_AMPA_Data_out$SB~HNK_AMPA_Data_out$Dose, var.equal = TRUE)
#Assumes equal variances
# t(17) = -2.1484; p = 0.04638 #AMPA binding differs between dose groups
# calc eta^2
((-2.1484)**2/((-2.1484)**2 + 17))
# eta^2 = 0.2135318, moderate effect size
#Because of literature suggesting higher LTP expression in the CA1 region of the hippocampus
after
#ketamine administration, we conducted an exploratory analysis of binding in only the CA1
region
#for the same sample above.
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#Descriptive stats for CA1 binding data
CA1Descriptive <- summarySE(HNK_AMPA_Data, measurevar='SB_CA1', groupvars =
'Dose')
#Calculate residuals for CA1 binding data
CA1_residuals <- HNK_AMPA_Data %>% group_by(Dose) %>% mutate(Group_mean =
mean(SB_CA1)) %>%
ungroup() %>% mutate(Residuals = SB_CA1 - Group_mean) %>%
select(Rat.ID,Dose, SB_CA1, Residuals) %>% arrange(Dose)
sum(CA1_residuals$Residuals)
# checksum = 4.26e-14 please check that you get the same value
## I get sum= 2.131628e-14
#Check CA1 residuals for normality using the Lilliefors test.
lillie.test(CA1_residuals$Residuals)
#D=017384, p=0.1167, CA1 binding data is normally distributed
#Since data is normal, check for outliers using Pierce's criterion.
Out_analysis <- OutlierPierce(CA1_residuals$Residuals) #R54
CA1_residuals <- cbind(CA1_residuals,Out_analysis)
CA1_outlier <- CA1_residuals %>% filter(Out_analysis == 'TRUE')
#Remove outlier from the data set.
HNK_AMPA_Data_out <- HNK_AMPA_Data %>% filter(Rat.ID != 'R00054')
#Analyze CA1 binding data using an independent samples t-test.
var.test(HNK_AMPA_Data_out$SB_CA1~HNK_AMPA_Data_out$Dose)
#F(8,9)=2.0597, p=0.3025; variances are equal.
t.test(HNK_AMPA_Data_out$SB_CA1~HNK_AMPA_Data_out$Dose, var.equal = TRUE)
#t(17)= -2.6119, p= 0.01823
#calc eta^2
((-2.6119)^2/((-2.6119)^2 + 17))
#eta^2 = 0.28637, Moderately large effect size.
#There is higher AMPA expression observed in the CA1 region with rats dosed with 10mg/kg
(2R,6R)-HNK than vehicle.
#-------FIGURES
Quick_bar <- function(df, Ind_var, Dep_var, x_title, y_title, n_pos = 1, y_lim = c(0,NA)) {
# Dependencies
library(tidyverse)
library(viridis)
library(viridisLite)
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library(shadowtext)
# Derives mean, standard error, and group sample size
descriptives <- df %>% group_by(!!sym(Ind_var)) %>%
summarize(n = n(), mean = mean(.data[[Dep_var]]),sd = sd(.data[[Dep_var]]),se = sd/sqrt(n))
# Plots a bar graph based on the called data frame
plot <- ggplot(descriptives, aes(x = as.factor(!!sym(Ind_var)) , y = mean, fill =
as.factor(!!sym(Ind_var)))) +
geom_bar(stat = 'identity', position = position_dodge(), color = 'black', size = 1.5) +
geom_errorbar(aes(ymin = mean - se, ymax = mean + se, width = 0.25), size = 1.1) +
theme_classic() +
scale_fill_viridis_d(begin = 0, end = 0.95, option = 'plasma', aesthetics = 'fill') +
geom_shadowtext(y = n_pos,label = sprintf('N=%s', paste0(descriptives$n)), size = 6, fontface
= 'bold') +
theme_classic() + labs(x = x_title, y = y_title) + theme(legend.position = 'none') +
theme(axis.text = element_text(size = 16, face = 'bold'),
axis.title = element_text(size = 18, face = 'bold'),
plot.title = element_text(hjust = 0.5, size = 20, face = "bold"),
legend.title = element_text(size = 14, face = "bold"),
legend.text = element_text(size = 12, face = 'bold')) + ylim(y_lim)
return(plot)
}
Quick_violin <- function(df, Ind_var, Dep_var, x_title, y_title, y_lim = c(0,NA)) {
# Dependencies
library(tidyverse)
library(viridis)
library(viridisLite)
library(shadowtext)
# Derives mean, standard error, and group sample size
descriptives <- df %>% group_by(!!sym(Ind_var)) %>%
summarize(n = n(), mean = mean(.data[[Dep_var]]),sd = sd(.data[[Dep_var]]),se = sd/sqrt(n))
# Plots a violin plot based on the called data frame
plot <- ggplot(df, aes(x = as.factor(!!sym(Ind_var)) , y = .data[[Dep_var]], fill =
as.factor(!!sym(Ind_var)))) +
geom_violin(color = 'black', size = 1.5) +
scale_fill_viridis_d(begin = 0, end = 0.95, option = 'plasma', aesthetics = 'fill') +
theme_classic() + labs(x = x_title, y = y_title) + theme(legend.position = 'none') +
geom_pointrange(data = descriptives, aes(y = mean, ymin = mean-se, ymax = mean+se), size
= 1.1) +
ylim(y_lim) +
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theme(axis.text = element_text(size = 16, face = 'bold'),
axis.title = element_text(size = 18, face = 'bold'),
plot.title = element_text(hjust = 0.5, size = 20, face = "bold"),
legend.title = element_text(size = 14, face = "bold"),
legend.text = element_text(size = 12, face = 'bold'))
return(plot)
}
AMPA_A <- Quick_bar(HNK_AMPA_Data_out, 'Dose','SB','(2R,6R)HNK Dose \n(mg/kg, 24
hr i.p.)',
'[3H]AMPA Binding (AU)', 5, c(0,60)) +
theme(plot.title = element_text(hjust = 0)) + annotate("text",x=2,y=55,label="*", size=10)
AMPA_B <- Quick_violin(HNK_AMPA_Data_out, 'Dose','SB','(2R,6R)HNK Dose \n(mg/kg,
24 hr i.p.)',
'[3H]AMPA Binding (AU)', c(0,65)) +
theme(plot.title = element_text(hjust = 0))
AMPA_A
AMPA_B
CA1_A <- Quick_bar(HNK_AMPA_Data_out, 'Dose','SB_CA1','(2R,6R)HNK Dose \n(mg/kg,
24 hr i.p.)',
'[3H]AMPA Binding (AU)', 5, c(0,65)) +
theme(plot.title = element_text(hjust = 0)) + annotate("text",x=2,y=60,label="*", size=10)
CA1_B <- Quick_violin(HNK_AMPA_Data_out, 'Dose','SB_CA1','(2R,6R)HNK Dose
\n(mg/kg, 24 hr i.p.)',
'[3H]AMPA Binding (AU)', c(0,65)) +
theme(plot.title = element_text(hjust = 0))
CA1_A
CA1_B

